UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

Mark one

☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended ~~January~~April 3130, 2025

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from ___________________ to ___________________

Commission File Number 001-09974

ENZO BIOCHEM, INC.

(Exact name of registrant as specified in its charter)

New York		13-2866202
(State or Other Jurisdiction of		(IRS. Employer
Incorporation or Organization)		Identification No.)

21 Executive Blvd. Farmingdale, New York		11735
(Address of Principal Executive office)		(Zip Code)

(631) 755-5500

(Registrant’s telephone number, including area code)

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol		Name of each exchange on which registered
Common stock $0.01 par value		~~ENZ~~ENZB		~~The~~OTC ~~New~~Markets ~~York Stock Exchange~~OTCQX

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant has required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted and posted pursuant to Rule 45 of Regulation S-T (§232.405 of that chapter) during the preceding 12 months (or such shorter period that the registrant was required to submit and post such files).

Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer a smaller reporting company, or an emerging growth company (as defined in Rule 12b-2 of the Exchange Act).

Large accelerated filer	☐	Accelerated filer	☐
Non-accelerated filer	☒	Smaller reporting company	☒
Emerging growth company	☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Yes ☐ No ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act.)

Yes ☐ No ☒

As of ~~March~~June 10, 2025, the Registrant had 52,402,804 shares of common stock outstanding.

ENZO BIOCHEM, INC.

FORM 10-Q

~~January~~April 3130, 2025

INDEX

	PART I - FINANCIAL INFORMATION
Item 1.	Financial Statements	1
	Consolidated Balance Sheets – January 31, 2025 (unaudited) and July 31, 2024	1
	Consolidated Balance Sheets – April 30, 2025 (unaudited) and July 31, 2024	1
	Consolidated Statements of Operations for the three and six months ended January 31, 2025 and 2024 (unaudited)	2
	Consolidated Statements of Operations for the three and nine months ended April 30, 2025 and 2024 (unaudited)	2
	Consolidated Statements of Comprehensive Loss for the three and six months ended January 31, 2025 and 2024 (unaudited)	3
	Consolidated Statements of Comprehensive Loss for the three and nine months ended April 30, 2025 and 2024 (unaudited)	3
	Consolidated Statements of Stockholders’ Equity for the three and six months ended January 31, 2025 and 2024(unaudited)	4
	Consolidated Statements of Stockholders’ Equity for the three and nine months ended April 30, 2025 and 2024 (unaudited)	4
	Consolidated Statements of Cash Flows for the six months ended January 31, 2025 and 2024 (unaudited)	6
	Consolidated Statements of Cash Flows for the nine months ended April 30, 2025 and 2024 (unaudited)	6
	Notes to the Consolidated Financial Statements	7
Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	2624
Item 3.	Quantitative and Qualitative Disclosures About Market Risk	3231
Item 4.	Controls and Procedures	3231
	PART II - OTHER INFORMATION
Item 1.	Legal Proceedings	3332
Item 1A.	Risk Factors	3332
Item 6.	Exhibits	3332
Signatures		3433

PART I FINANCIAL INFORMATION

ITEM 1 FINANCIAL STATEMENTS

ENZO BIOCHEM, INC.

CONSOLIDATED BALANCE SHEETS

(in thousands, except share and per share data)

	January 31, 2025 (unaudited)			July 31, 2024
	April 30, 2025 (unaudited)			July 31, 2024
ASSETS
Current assets:
Cash and cash equivalents	$	4036,~~297~~693		$	52,371
Cash in escrow		—			5,000
Accounts receivable, net		4,~~245~~309			3,988
Inventories, net		5,~~987~~714			6,832
Prepaid expenses and other current assets		1,~~688~~562			1,840
Total current assets		5248,~~217~~278			70,031
Property, plant, and equipment, net		12,~~303~~380			12,367
Right-of-use assets		2,~~563~~472			2,836
Other assets		~~427~~386			530
Total assets	$	6763,~~510~~516		$	85,764
LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities:
Accounts payable – trade	$	~~672~~1,395		$	1,376
Accrued liabilities		5,~~392~~170			5,714
Current portion of operating lease liabilities		~~817~~881			841
Other current liabilities		73			76
Current liabilities of discontinued operations, net		109,~~222~~492			16,787
Total current liabilities		17,~~176~~011			24,794
Operating lease liabilities, non-current		21,~~102~~920			2,403
Long term debt		~~146~~129			189
Non-current liabilities of discontinued operations, net		1,~~470~~058			2,266
Total liabilities	$	20,~~894~~118		$	29,652
Contingencies – see Note 13
Stockholders’ equity:
Preferred Stock, $.01 par value; authorized 25,000,000 shares; no shares issued or outstanding		—			—
Common Stock, $.01 par value; authorized 75,000,000 shares; shares issued and outstanding: 52,402,804 at January 31, 2025 and 52,244,074 at July 31, 2024		523			521
Common Stock, $.01 par value; authorized 75,000,000 shares; shares issued and outstanding: 52,402,804 at April 30, 2025 and 52,244,074 at July 31, 2024		523			521
Additional paid-in capital		343,~~159~~333			348,134
Accumulated deficit		(~~299~~302,~~339~~129	)		(294,428	)
Accumulated other comprehensive income		21,~~273~~671			1,885
Total stockholders’ equity		4643,~~616~~398			56,112
Total liabilities and stockholders’ equity	$	6763,~~510~~516		$	85,764

The accompanying notes are an integral part of these consolidated financial statements.

ENZO BIOCHEM, INC.

CONSOLIDATED STATEMENTS OF OPERATIONS (~~UNAUDITED~~unaudited) (in thousands, except per share data)

	Three Months Ended January 31,						Six Months Ended January 31,
	Three Months Ended April 30,						Nine Months Ended April 30,
	2025			2024			2025			2024
Revenues	$	76,~~334~~402		$	8,~~553~~022		$	1319,~~546~~948		$	1624,~~359~~381
Operating costs and expenses:
Cost of revenues		3,~~549~~755			4,~~329~~289			710,~~230~~985			812,~~680~~969
Cost of revenues – inventory provision		—163			—			~~252~~415			—
Research and development		~~479~~504			~~580~~605			1,~~041~~545			12,~~429~~035
Selling, general and administrative		4,~~558~~904			54,~~068~~479			914,~~441~~345			1216,~~070~~550
Legal and related expense, net		~~350~~465			~~761~~692			~~808~~1,273			12,~~835~~527
Total operating costs and expenses		89,~~936~~791			10,~~738~~065			1828,~~772~~563			2434,~~014~~081
Operating loss		(13,~~602~~389	)		(2,~~185~~043	)		(58,~~226~~615	)		(79,~~655~~700	)
Other income (expense), net:
Interest, net		~~462~~384			~~893~~726			1,~~082~~466			12,~~870~~595
Change in fair value of convertible debentures		—			(~~383~~384	)		—			(~~711~~1,095	)
Other		~~126~~123			~~119~~94			~~250~~373			~~276~~373
Foreign exchange (loss) gain		~~(234~~508	)		~~693~~(524	)		~~(425~~83	)		(~~318~~842	)
Total other income, net		354			1,322			907			1,117
Total other income (expense), net		1,015			(88	)		1,922			1,031
Loss before income taxes		(12,~~248~~374	)		(~~863~~2,131	)		(46,~~319~~693	)		(68,~~538~~669	)
Income taxes		—			—			—			—
Net loss from continuing operations		(12,~~248~~374	)		(~~863~~2,131	)		(46,~~319~~693	)		(68,~~538~~669	)
Net loss from discontinued operations		(~~287~~416	)		(~~2,198~~889	)		(~~592~~1,008	)		(34,~~139~~028	)
Net loss	$	(12,~~535~~790	)	$	(3,~~061~~020	)	$	(47,~~911~~701	)	$	(912,~~677~~697	)
Net loss per common share – basic and diluted:
Continuing operations	$	(0.0204	)	$	(0.0204	)	$	(0.0813	)	$	(0.1317	)
Discontinued operations		(0.01	)		(0.0402	)		(0.0102	)		(0.0608	)
Total net loss per basic and diluted common share	$	(0.0305	)	$	(0.06	)	$	(0.0915	)	$	(0.1925	)
Weighted average common shares outstanding:
Basic and diluted		52,~~297~~403			5051,~~490~~214			52,~~271~~315			50,~~337~~629

The accompanying notes are an integral part of these consolidated financial statements.

ENZO BIOCHEM, INC.

CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS

(unaudited)

(in thousands)

	Three Months Ended January 31,						Six Months Ended January 31,
	Three Months Ended April 30,						Nine Months Ended April 30,
	2025			2024			2025			2024
Net loss	$	(12,~~535~~790	)	$	(3,~~061~~020	)	$	(47,~~911~~701	)	$	(912,~~677~~697	)
Other comprehensive (loss) income:
Foreign currency translation adjustments		~~313~~(602	)		~~(700~~452	)		~~388~~(214	)		~~168~~620
Comprehensive loss	$	(13,~~222~~392	)	$	(32,~~761~~568	)	$	(47,~~523~~915	)	$	(912,~~509~~077	)

The accompanying notes are an integral part of these consolidated financial statements.

ENZO BIOCHEM, INC.

CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY

Three Months Ended ~~January~~April 3130, 2025 and 2024

(unaudited)

(in thousands, except share data)

	Common Stock Shares Issued		Common Stock Amount		Additional Paid-in Capital		Accumulated Deficit			Accumulated Other Comprehensive Income			Total Stockholders’ Equity
Balance at October 31, 2024		52,244,074	$	521	$	342,981	$	(297,804	)	$	1,960		$	47,658
Net loss for the period ended January 31, 2025		—		—		—		(1,535	)		—			(1,535	)
Share-based compensation charges		—		—		178		—			—			178
Vesting of restricted stock units		158,730		2		—		—			—			2
Foreign currency translation adjustments		—		—		—		—			313			313
Balance at January 31, 2025		52,402,804	$	523	$	343,159	$	(299,339	)	$	2,273		$	46,616
Net loss for the period ended April 30, 2025		—		—		—		(2,790	)		—			(2,790	)
Share-based compensation charges		—		—		174		—			—			174
Foreign currency translation adjustments		—		—		—		—			(602	)		(602	)
Balance at April 30, 2025		52,402,804	$	523	$	343,333	$	(302,129	)	$	1,671		$	43,398

	Common Stock Shares Issued		Common Stock Amount		Additional Paid-in Capital		Accumulated Deficit			Accumulated Other Comprehensive Income			Total Stockholders’ Equity
Balance at October 31, 2023		50,489,771	$	504	$	345,991	$	(274,966	)	$	2,746		$	74,275
Net loss for the period ended January 31, 2024		—		—		—		(3,061	)		—			(3,061	)
Share-based compensation charges		—		—		261		—			—			261
Foreign currency translation adjustments		—		—		—		—			(700	)		(700	)
Balance at January 31, 2024		50,489,771	$	504	$	346,252	$	(278,027	)	$	2,046		$	70,775
Net loss for the period ended April 30, 2024		—		—		—		(3,020	)		—			(3,020	)
Share-based compensation charges		—		—		207		—			—			207
Vested restricted and performance stock units issued		249,912		2		—		—			—			2
Issuance of common stock for employee 401(k) plan match		487,852		5		610		—			—			615
Foreign currency translation adjustments		—		—		—		—			452			452
Balance at April 30, 2024		51,227,535	$	511	$	347,069	$	(281,047	)	$	2,498		$	69,031

ENZO BIOCHEM, INC.

CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY

~~Six~~Nine Months Ended ~~January~~April 3130, 2025 and 2024

(unaudited)

(in thousands, except share data)

	Common Stock Shares Issued		Common Stock Amount		Additional Paid-in Capital			Accumulated Deficit			Accumulated Other Comprehensive Income			Total Stockholders’ Equity
Balance at July 31, 2024		52,244,074	$	521	$	348,134		$	(294,428	)	$	1,885		$	56,112
Net loss for the period ended January 31, 2025		—		—		—			(4,911	)		—			(4,911	)
Net loss for the period ended April 30, 2025		—		—		—			(7,701	)		—			(7,701	)
Share-based compensation charges		—		—		~~349~~523			—			—			~~349~~523
Vesting of restricted stock units		158,730		2		—			—			—			2
Payment of cash dividend						(5,324	)								(5,324	)
Foreign currency translation adjustments		—		—		—			—			~~388~~(214	)		~~388~~(214	)
Balance at January 31, 2025		52,402,804	$	523	$	343,159		$	(299,339	)	$	2,273		$	46,616
Balance at April 30, 2025		52,402,804	$	523	$	343,333		$	(302,129	)	$	1,671		$	43,398

	Common Stock Shares Issued		Common Stock Amount		Additional Paid-in Capital		Accumulated Deficit			Accumulated Other Comprehensive Income		Total Stockholders’ Equity
Balance at July 31, 2023		49,997,631	$	499	$	344,435	$	(268,350	)	$	1,878	$	78,462
Net loss for the period ended January 31, 2024		—		—		—		(9,677	)		—		(9,677	)
Net loss for the period ended April 30, 2024		—		—		—		(12,697	)		—		(12,697	)
Vested restricted stock unit issuances		144,530		1		—		—			—		1
Vested restricted and performance stock unit issued		394,442		4		—		—			—		4
Common stock issued for Asset Purchase Agreement bonus payment		347,610		43		481		—			—		~~485~~484
Share-based compensation charges		—		—		1,~~336~~543		—			—		1,~~336~~543
Foreign currency translation adjustments		—		—		—		—			168		168
Issuance of common stock for employee 401(k) plan match		487,852		5		610		—			—		615
Balance at January 31, 2024		50,489,771	$	504	$	346,252	$	(278,027	)	$	2,046	$	70,775
Foreign currency translation adjustments		—		—		—		—			620		620
Balance at April 30, 2024		51,227,535	$	511	$	347,069	$	(281,047	)	$	2,498	$	69,031

The accompanying notes are an integral part of these consolidated financial statements.

ENZO BIOCHEM, INC.

CONSOLIDATED STATEMENTS OF CASH FLOWS

(unaudited)

(in thousands)

	Six Months Ended January 31,
	Nine Months Ended April 30,
	2025			2024
Cash flows from operating activities:
Net loss	$	(47,~~911~~701	)	$	(912,~~677~~697	)
Adjustments to reconcile net loss to net cash used in operating activities:
Change in fair value of convertible debentures		—			~~711~~1,095
Depreciation and amortization of property, plant and equipment		~~637~~955			~~537~~874
Share-based compensation charges		~~349~~523			1,~~336~~543
Share-based 401(k) employer match expense		~~213~~—			~~362~~494
Unrealized foreign exchange loss		396			240
Unrealized foreign exchange (gain) loss		(127	)		764
Gain on operating lease termination		—			(554	)
Changes in operating assets and liabilities:
Accounts receivable		(~~554~~377	)		12,~~252~~475
Inventories		~~560~~1,064			~~192~~636
Prepaid expenses and other assets		~~501~~729			(~~272~~88	)
Accounts payable – trade		(~~942~~61	)		(7,~~097~~654	)
Accrued liabilities, other current liabilities and other liabilities		(79,~~265~~241	)		(912,~~342~~062	)
Total adjustments		(6,~~105~~535	)		(12,~~635~~477	)
Net cash used in operating activities		(1114,~~016~~236	)		(2225,~~312~~174	)
Cash flows from investing activities:
Release of escrowed cash from Asset Purchase Agreement		5,000			—
Capital expenditures		(~~518~~904	)		(~~279~~422	)
Net cash provided by (used in) investing activities		4,~~482~~096			(~~279~~422	)
Cash flows from financing activities:
Payment of cash dividend		(5,324	)		—
Repayments under loan agreement and capital leases		(37	)		(73	)
Repayments under loan agreement		(79	)		(110	)
Cash payments for taxes related to net share settlements of equity awards		(163	)		(~~467~~474	)
Net cash used in financing activities		(5,~~524~~566	)		(~~540~~584	)
Effect of exchange rate changes on cash and cash equivalents		~~(16~~28	)		(137	)
Decrease in cash and cash equivalents		(1215,~~074~~678	)		(2326,~~132~~217	)
Cash and cash equivalents - beginning of period		52,371			83,373
Cash and cash equivalents - end of period	$	4036,~~297~~693		$	6057,~~241~~156

The accompanying notes are an integral part of these consolidated financial statements.

ENZO BIOCHEM, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

As of ~~January~~April 3130, 2025

(unaudited)

(Dollars in thousands except share data)

Note 1 – Basis of Presentation

Enzo Biochem, Inc. (the “Company”, “we”, “our” or “Enzo”) has operated as a life sciences company for over 45 years. The primary business of Enzo today is conducted through its Enzo Life Sciences division (“Enzo Life Sciences”), which focuses on labeling and detection technologies from DNA to whole cell analysis, including a comprehensive portfolio of thousands of high-quality products, including antibodies, genomic probes, assays, biochemicals, and proteins. The Company’s proprietary products and technologies play central roles in translational research and drug development areas, including cell biology, genomics, assays, immunohistochemistry, and small molecule chemistry. Enzo strives to enable a healthier world using scientific innovation through drug discovery, development and diagnostic solutions.

The accompanying consolidated financial statements include the accounts of Enzo Biochem, Inc. and its wholly-owned subsidiaries, Enzo Life Sciences, Inc. (“Enzo Life Sciences”), Enzo Therapeutics, Inc. (“Enzo Therapeutics”), Enzo Realty LLC (“Enzo Realty”), and Enzo Realty II LLC (“Enzo Realty II”), collectively or with one or more of its subsidiaries referred to as the “Company” or “Companies.” The financial statements also include as discontinued operations the accounts of its wholly-owned subsidiary Enzo Clinical Labs, Inc. (“Enzo Clinical Labs”). Effective July 24, 2023, we completed the sale of certain assets used in our clinical services operations to Laboratory Corporation of America Holdings, a Delaware corporation (“Labcorp”), and thereby exited the clinical services business. See Note 2.

~~We have one reportable segment, Products.~~ The consolidated balance sheet as of ~~January~~April 3130, 2025, the consolidated statements of operations, comprehensive loss and stockholders’ equity for the three and ~~six~~nine months ended ~~January~~April 3130, 2025 and 2024, and the consolidated statements of cash flows for the ~~six~~nine months ended ~~January~~April 3130, 2025 and 2024 (the “interim statements”) are unaudited. In the opinion of management, all adjustments (which include normal recurring adjustments) necessary to present fairly the financial position and operating results for the interim periods have been made. Certain information and footnote disclosure, normally included in annual financial statements prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”), have been condensed or omitted. The interim statements should be read in conjunction with the consolidated financial statements for the fiscal year ended July 31, 2024 and notes thereto contained in the Company’s Annual Report on Form 10-K filed with the Securities and Exchange Commission. The consolidated balance sheet at July 31, 2024 has been derived from the audited financial statements at that date. The results of operations for the three and ~~six~~nine months ended ~~January~~April 3130, 2025 are not necessarily indicative of the results that may be expected for the fiscal year ending July 31, 2025. We have one reportable segment, Products.

Principles of consolidation

The accompanying consolidated financial statements have been prepared in conformity with U.S. GAAP and include the accounts of the Company and its wholly-owned subsidiaries. All intercompany transactions and balances have been eliminated.

Use of Estimates

The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting periods. Actual results could differ from those estimates.

Contingencies

Contingencies are evaluated and a liability is recorded when the matter is both probable and reasonably estimable. Gain contingencies are evaluated and not recognized until the gain is realizable or realized.

Foreign Currency Translation/Transactions

The Company has determined that the functional currency for its foreign subsidiaries is the local currency. For financial reporting purposes, assets and liabilities denominated in foreign currencies are translated at current exchange rates and profit and loss accounts are translated at weighted average exchange rates. Resulting foreign currency translation adjustments are recognized as other comprehensive income (loss) in the consolidated statements of comprehensive loss and are included as a separate component of stockholders’ equity as accumulated other comprehensive income. Gains or losses resulting from transactions entered into in other than the functional currency are recorded as foreign exchange gains and losses in the consolidated statements of operations.

Fair Value Measurements

The Company determines fair value measurements used in its consolidated financial statements based upon the exit price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants exclusive of any transaction costs, as determined by either the principal market or the most advantageous market. Inputs used in the valuation techniques to derive fair values are classified based on a three-level hierarchy. The basis for fair value measurements for each level within the hierarchy is described below with Level 1 having the highest priority and Level 3 having the lowest.

Level 1 Quoted prices in active markets for identical assets or liabilities.

Level 2 Quoted prices for similar assets or liabilities in active markets; quoted prices for identical or similar instruments in markets that are not active; and model-derived valuations in which all significant inputs are observable in active markets.

Level 3 Valuations derived from valuation techniques in which one or more significant inputs are unobservable.

Cash and cash equivalents

Cash and cash equivalents consist of demand deposits with banks and highly liquid money market funds. At ~~January~~April 3130, 2025 and July 31, 2024, the Company had cash and cash equivalents in foreign bank accounts of $~~420~~484 and $391, respectively.

Concentration of Credit Risk

Financial instruments that potentially subject the Company to concentrations of credit risk primarily consist of cash and cash equivalents and accounts receivable. The Company believes the fair value of the aforementioned financial instruments approximates the cost due to the immediate or short-term nature of these items. At ~~January~~April 3130, 2025 and July 31, 2024, the Company had cash deposited in certain financial institutions in excess of federally insured levels. The Company regularly monitors the financial stability of these financial institutions and believes that it is not exposed to any significant credit risk in cash and cash equivalents or restricted cash.

Concentration of credit risk with respect to the Company’s Products segment is mitigated by the diversity of the Company’s customers and their dispersion across many different geographic regions. To reduce risk, the Company routinely assesses the financial strength of these customers and, consequently, believes that its accounts receivable credit exposure with respect to these customers is limited.

Income Taxes

The Company accounts for income taxes under the liability method of accounting for income taxes. Under the liability method, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. The liability method requires that any tax benefits recognized for net operating loss carry forwards and other items be reduced by a valuation allowance when it is more likely than not that the benefits may not be realized. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. Under the liability method, the effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date.

The Company carries a valuation allowance equal to domestic and foreign net deferred tax assets as of January 31, 2025 and July 31, 2024. The Company believes that the valuation allowance is necessary as it is not more likely than not that the deferred tax assets will not be realized in the foreseeable future based on positive and negative evidence available at this time. This conclusion was reached because of uncertainties relating to future taxable income, in terms of both its timing and its sufficiency, which would enable the Company to realize the deferred tax assets.8

The Company carries a valuation allowance equal to domestic and foreign net deferred tax assets as of April 30, 2025 and July 31, 2024. The Company believes that the valuation allowance is necessary as it is not more likely than not that the deferred tax assets will not be realized in the foreseeable future based on positive and negative evidence available at this time. This conclusion was reached because of uncertainties relating to future taxable income, in terms of both its timing and its sufficiency, which would enable the Company to realize the deferred tax assets.

Effect of New Accounting Pronouncements

Pronouncements Issued but Not Yet Adopted

In December 2023, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures. The amended guidance enhances income tax disclosures primarily related to the effective tax rate reconciliation and income taxes paid information. This guidance requires disclosure of specific categories in the effective tax rate reconciliation and further information on reconciling items meeting a quantitative threshold. In addition, the amended guidance requires disaggregating income taxes paid (net of refunds received) by federal, state, and foreign taxes. It also requires disaggregating individual jurisdictions in which income taxes paid (net of refunds received) is equal to or greater than five percent of total income taxes paid (net of refunds received). The amended guidance will be effective for our fiscal year beginning August 1, 2025. The guidance can be applied either prospectively or retrospectively. We are currently in the process of evaluating the impact this amended guidance may have on the footnotes to our consolidated financial statements.

In November 2023, FASB issued ASU No. 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures (ASU 2023-07), which requires an enhanced disclosure of significant segment expenses on an annual and interim basis. This guidance will be effective for our annual period ending July 31, 2025 and our interim periods beginning August 1, 2025. Upon adoption, we expect the guidance will be applied retrospectively to all prior periods presented in the consolidated financial statements. We do not expect the adoption of this guidance to have a material impact on our consolidated financial statements.

In November 2024, FASB issued ASU No. 2024-03, Disaggregation on Income Statement Expenses (DISE), which specifies additional disclosure requirements. The new guidance requires additional disclosures, including the composition of certain expense line items (such as purchases of inventory, employee compensation, and “other expenses”) and a separate disclosure for selling expenses. This guidance will be effective for our annual period ending July 31, ~~2027~~2028 and our interim periods beginning August 1, ~~2027~~2028. Early adoption is permitted. We are currently evaluating the impact that the adoption of ASU 2024-03 will have on our consolidated financial statement disclosures.

We reviewed all other recently issued accounting pronouncements and have concluded they are not applicable or not expected to be significant to the accounting for our operations.

Reclassifications

Certain prior period amounts have been reclassified to conform to the current period presentation. These reclassifications had no effect on the reported results of operations or discontinued operations.

Note 2 – Discontinued operations

Prior to July 24, 2023, we operated a clinical laboratory, doing business as Enzo Clinical Labs, which provided reference, molecular and esoteric diagnostic medical testing services in the New York, New Jersey, and Connecticut medical communities. Effective July 24, 2023, we completed the sale of certain assets used in the operation of Enzo Clinical Labs and the assignment of certain clinical lab liabilities to Labcorp for an aggregate purchase price of $113.25 million in cash. In accordance with the sale, we ceased our clinical services operations. Excluded from the sale of the clinical services assets were its cash and accounts receivable. As a consequence of the sale, we have classified as discontinued operations all income and expenses attributable to the clinical services business for the fiscal year 2025 and 2024 periods presented.

~~The following table sets forth the condensed operating results of the discontinued operations for the three and six months ended January 31:~~9

	Three Months Ended January 31						Six Months Ended January 31
	2025			2024			2025			2024
General and administrative expense	$	221		$	813		$	471		$	2,250
Other expense		66			1,385			121			889
Loss from discontinued operations	$	(287	)	$	(2,198	)	$	(592	)	$	(3,139	)

The following table sets forth the condensed operating results of the discontinued operations for the three and nine months ended April 30:

	Three Months Ended April 30						Nine Months Ended April 30
	2025			2024			2025			2024
General and administrative expense	$	270		$	835		$	740		$	3,085
Other expense – net		146			54			268			943
Loss from discontinued operations	$	(416	)	$	(889	)	$	(1,008	)	$	(4,028	)

The following table sets forth the condensed carrying amounts of major classes of assets and liabilities of the discontinued operations as of the dates indicated:

	January 31, 2025		July 31, 2024
	April 30, 2025		July 31, 2024
Carrying amounts of major current assets included as part of discontinued operations:
Prepaid and other current	$	6834	$	182
Carrying amounts of major current liabilities included as part of discontinued operations:
Accrued liabilities and trade payables		87,~~232~~429		14,979
Operating lease liabilities and other		2,~~058~~097		1,990
Total current liabilities		109,~~290~~526		16,969
Current liabilities of discontinued operations, net	$	109,~~222~~492	$	16,787
Carrying amount of major non-current assets included as part of discontinued operations:
Right-of-use assets	$	~~1,071~~945	$	1,308
Other		6162		75
Total non-current assets		1,~~132~~007		1,383
Carrying amount of major non-current liabilities included as part of discontinued operations:
Operating lease liabilities and other		2,~~602~~065		3,649
Non-current liabilities of discontinued operations, net	$	1,~~470~~058	$	2,266

During the ~~six~~nine months ended ~~January~~April 3130, 2025, the cash used in operating activities of the discontinued operations was $78,~~213~~397, primarily for reductions of trade payables and accrued liabilities, and the period loss. During the ~~six~~ nine months ended ~~January~~April 3130, 2024, the cash used in operating activities of the discontinued operations was $1114,~~304~~219, primarily for reductions of trade payables and accrued liabilities, and the period loss.

Note 3 – Net loss per share

Basic net loss per share represents net loss divided by the weighted average number of common shares outstanding during the period. The dilutive effect of potential common shares, consisting of outstanding stock options, and unvested restricted stock units and performance stock units, is determined using the treasury stock method. As a result of the net loss for the three and ~~six~~nine months ended ~~January~~April 3130, 2025 and 2024, diluted weighted average shares outstanding are the same as basic weighted average shares outstanding, and do not include the potential common shares from stock options, restricted stock units, or warrants because to do so would be anti-dilutive.

For the three and ~~six~~nine months ended ~~January~~April 3130, 2025, the effect of ~~approximately~~ 2approximately 1,~~105~~611,000 and 21,~~115~~838,000, respectively, of outstanding “out of the money” options to purchase common shares and the effect of approximately ~~zero and 10~~529,~~700,~~000 ~~respectively, of~~ outstanding restricted stock units at April 30, 2025 were excluded from the calculation of diluted net (loss) per share because their effect would be anti-dilutive. Also, for the three and six months ended January 31, 2025, the effect of approximately 1,686,000 and 1,270,000 shares related to 1,000,000 warrants was excluded from the calculation of diluted weighted average shares outstanding because their effect would be anti-dilutive. The warrants relate to the debentures which were repaid in May 2024. The warrants are eligible for any dividends paid on the common stock and are therefore considered to be participating securities which do not have any contractual obligation to share in the Company’s losses. The impact on net loss per share under the two-class method was not material.

For the three and six months ended January 31, 2024, the effect of approximately 2,474,000 and 2,897,000, respectively, of outstanding “out of the money” options to purchase common shares and the effect of approximately 280,000 and 129,000, respectively, of outstanding restricted stock units were excluded from the calculation of diluted net (loss) income per share because their effect would be anti-dilutive. During the three and six months ended January 31, 2024, the effect of approximately 754,000 and 647,000, respectively, of shares related to warrants and the effect of approximately 1,535,000 and 1,372,000, respectively of shares related to the assumed conversion of debentures were excluded from the calculation of diluted weighted average shares outstanding because their effect would be anti-dilutive.10

For the three and nine months ended April 30, 2025, the effect of an assumed exercise of 1,000,000 “out of the money” warrants and the hypothetical shares which would be bought back was excluded from the calculation of diluted weighted average shares outstanding because the effect would also be anti-dilutive.

For the three and nine months ended April 30, 2024, the effect of approximately 1,832,000 and 2,542,000, respectively, of outstanding “out of the money” options to purchase common shares and the effect of approximately 77,000 and 133,000, respectively, of outstanding restricted stock units were excluded from the calculation of diluted net (loss) income per share because their effect would be anti-dilutive. During the three and nine months ended April 30, 2024, the effect of approximately 848,000 and 688,000, respectively, of shares related to warrants and the effect of approximately 1,688,000 and 1,438,000, respectively of shares related to the assumed conversion of debentures were excluded from the calculation of diluted weighted average shares outstanding because their effect would be anti-dilutive.

The warrants relate to the convertible debentures, which were repaid in May 2024. The warrants are eligible for any dividends paid on the common stock and are therefore considered to be participating securities which do not have any contractual obligation to share in the Company’s losses. The impact on net loss per share under the two-class method was not material for any period presented.

Note 4 – Revenue Recognition

Products Revenue

The Company generates revenue from the sale of our single-use products used in the identification of genomic information. Revenue is recorded net of sales tax. The Company considers revenue to be earned when all of the following criteria are met: the Company has a contract with a customer that creates enforceable rights and obligations; promised products are identified; the transaction price is determinable; and the Company has transferred control of the promised items to the customer. A performance obligation is a promise in a contract to transfer a distinct good or service to the customer, and is the unit of account in the contract. The transaction price for the contract is measured as the amount of consideration the Company expects to receive in exchange for the goods expected to be transferred. A contract’s transaction price is allocated to each distinct performance obligation and recognized as revenue when, or as, control of the distinct good or service is transferred. Transfer of control for the Company’s products is generally at shipment or delivery, depending on contractual terms, but occurs when title and risk of loss transfers to the customer which represents the point in time when the customer obtains the use of and substantially all of the remaining benefit of the product. As such, the Company’s performance obligation related to product sales is satisfied at a point in time. The Company recognizes a receivable when it has an unconditional right to payment, which represents the amount the Company expects to collect in a transaction and is most often equal to the transaction price in the contract. Payment terms for shipments to end-user and distributor customers may range from 30 to 90 days. Amounts billed to customers for shipping and handling are included in revenue, while the related shipping and handling costs are reflected in cost of revenues.

Products revenue by geography is as follows:

Three Months Ended January 31

Six Months Ended January 31

Three Months Ended April 30

Nine Months Ended April 30

2025

2024

2025

2024

United States

4,~~830~~054

54,~~166~~793

812,~~594~~646

914,~~801~~594

Europe

1,~~712~~706

2,~~286~~359

35,~~375~~082

46,~~424~~783

Asia Pacific

~~792~~642

~~1,101~~870

12,~~577~~220

23,~~134~~004

Products revenue

76,~~334~~402

8,~~553~~022

1319,~~546~~948

1624,~~359~~381

As of August 1, 2024 and 2023, accounts receivable from continuing operations was $3,988 and $4,808, respectively.

Note 5 – Supplemental disclosure for statement of cash flows

During the ~~six~~nine months ended ~~January~~April 3130, 2025 and 2024, interest paid by the Company was $3 and $~~184~~275, respectively.

For the ~~six~~nine months ended ~~January~~April 3130, 2025 and 2024, the net reductions in the measurement of right-of-use assets and operating lease liabilities, including those of discontinued operations, was $~~786~~1,187 and $~~254~~306, respectively and are included in cash flows ~~from~~used in operating activities. The changes are included in changes in accrued liabilities, ~~other~~ other current liabilities, and other liabilities in the ~~statement~~statements of cash flows.

The Company added new right-of-use assets and operating lease liabilities of $106 and $0 for the ~~six~~nine months ended ~~January~~April 3130, 2025 and 2024, respectively.

In connection with the completed sale of certain assets used in the operation of Enzo Clinical Labs at the end of fiscal 2023, $5,000 of escrowed proceeds are included in cash in escrow as of July 31, 2024. As of ~~January~~April 3130, 2025, these escrowed proceeds were released to the Company. In connection with the full payment of a mortgage in July 2023, the restricted cash collateral deposit of $1,000 was released during the nine months ended April 30, 2024.

During the ~~six~~nine months ended ~~January~~April 3130, 2025, the Company disbursed $163 for taxes related to net share settlement of a bonus paid in stock to a senior executive. During the ~~six~~nine months ended ~~January~~April 3130, 2024, the Company disbursed $467 for taxes related to net share settlement of bonuses paid in stock to a senior executive and a former senior executive.

For the ~~six~~nine months ended ~~January~~April 3130, 2025 and 2024, tax on capital ~~paid~~ paid by the Company was $8 and $23, respectively. During the ~~six~~nine months ended ~~January~~April 3130, 2024, state taxes paid on the gain on the completed sale of certain assets used in the operation of Enzo Clinical Labs were $729.

On October 29, 2024, the Board of Directors of the Company declared a special cash dividend of $0.10 per share on its common stock, which was paid on December 2, 2024, to the holders of record entitled to dividends as of the close of business on November 15, 2024. The total dividend paid was $5,324.

Note 6 – Inventories

Inventories, net consisted of the following as of the dates indicated:

	January 31, 2025		July 31, 2024
	April 30, 2025		July 31, 2024
Raw materials	$	1,~~156~~101	$	1,794
Work in process		2,~~415~~178		2,461
Finished products		2,~~416~~435		2,577
	$	5,~~987~~714	$	6,832

Note 7 – Convertible debentures

In May 2023, the Company consummated a Securities Purchase Agreement (the “Purchase Agreement”) with the Purchasers, as defined in the Purchase Agreement, and JGB Collateral, LLC, as collateral agent for the Purchasers (the “Agent”). Pursuant to the Purchase Agreement, the Company agreed to sell to the Purchasers (i) 10% Original Issue Discount Secured Convertible Debentures (the “Debentures”) with an aggregate principal amount of $7,608 and (ii) warrants (the “Warrants”) to purchase up to 1,000,000 shares of the Company’s common stock, par value $0.01 per share (the “Common Stock”), for an exercise price of $2.31 per share, subject to adjustments as set forth in the Warrants, for a total purchase price of $7,000. Pursuant to ASC 825, Fair Value Option, the Company made an irrevocable election at the time of issuance to report the Debentures at fair value with changes in fair value recorded through the Company’s consolidated statements of operations as other income (expense) in each reporting period. During the ~~six~~nine months ended ~~January~~April 3130, 2024, the change in fair value expense recorded was $~~711~~1,095.

Debentures

The Debentures bore interest at a rate of 10% per annum. The Debentures were convertible, at any time after their issuance date at the option of the Purchasers, into shares of Common Stock at a conversion price equal to $3.01 per share (the “Conversion Price”), subject to adjustment as set forth in the Debentures. Following the July 24, 2023 consummation of the Company’s sale of certain assets and assignment of certain liabilities of Enzo Clinical Labs, Inc., to Labcorp pursuant to the Asset Purchase Agreement dated March 16, 2023, the Company prepaid $4,000 of the outstanding principal amount prior to July 31, 2023. In May 2024, the Company repaid in full the remaining principal balance of $3,609.

Warrants

The Warrants are exercisable for five years from May 19, 2023, at an exercise price of $2.31 per share, subject, with certain exceptions, to adjustments in the event of stock splits, subsequent dilutive offerings and certain fundamental transactions, as more fully described in the Warrant. The Warrants are eligible for any dividends paid on common stock. The warrant holders were paid $100 in dividends in December 2024.

Registration Rights Agreement

In connection with the Purchase Agreement, the Company was obligated to file a registration statement pursuant to which the Purchasers could sell the Common Stock issuable upon the conversion of the Debentures and the exercise of the warrants in a public offering. There is no right to a conversion of the Debentures into shares as the Debentures have been repaid in full.

Note 8 – Long term debt

In April 2020, the Company’s subsidiary in Switzerland received a loan of CHF 400 (or $400, based on the foreign exchange rate as of July 31, 2020) from the Swiss government under the “Corona Krise” emergency loan program in response to the COVID-19 pandemic. This loan is uncollateralized and bears 0% interest. In January 2022, the bank agent of the Swiss government informed our subsidiary that the loan had to be fully amortized within a maximum of eight years and the first of semiannual amortization payments of CHF 33 began in March 2022. Based on this amortization schedule, the loan will be repaid by September 2027. The current portion of this loan is included in other current liabilities and the long term portion in long term debt – net as of ~~January~~April 3130, 2025 and July 31, 2024.

Minimum future annual principal payments under this agreement as of ~~January~~April 3130, 2025 are as follows:

July 31,	Total
2025	$	37-
2026		7381
2027		7381
2028		3640
Total principal payments		~~219~~202
Less: current portion, included in other current liabilities		(73	)
Long term debt – net	$	~~146~~129

Note 9 – Leases

The Company determines if an arrangement is or contains a lease at contract inception. The Company leases buildings, office space, and equipment through operating leases. Generally, a right-of-use asset, representing the right to use the underlying asset during the lease term, and a lease liability, representing the payment obligation arising from the lease, are recognized on the balance sheet at lease commencement based on the present value of the payment obligation. For operating leases, expense is recognized on a straight-line basis over the lease term. Short-term leases with an initial term of 12 months or less are not recorded on the balance sheet; the Company recognizes lease expense for these leases on a straight-line basis over the lease term. The Company primarily uses its incremental borrowing rate in determining the present value of lease payments as the Company’s leases generally do not provide an implicit rate.

The Company has lease agreements with (i) right-of-use asset payments and (ii) non-lease components (e.g., payments related to maintenance fees, utilities, etc.) which have generally been combined and accounted for as a single lease component. The Company’s leases have remaining terms of less than 1 year to 3 years. Certain of the Company’s leases have terms that include renewal options that are reasonably certain to be exercised. Certain of the Company’s lease agreements include rental payments adjusted periodically for inflation which are included in the lease liabilities.

The following table summarizes the Company’s right of use assets and associated liabilities of its continuing operations as of the dates indicated:

Leases	Balance Sheet Classification	~~January~~April 3130, 2025		July 31, 2024
Assets
Operating	Right-of-use assets	$	2,~~563~~472	$	2,836
Total lease assets		$	2,~~563~~472	$	2,836
Liabilities
Current:
Operating	Current portion of operating lease liabilities	$	~~817~~881	$	841
Non-current:
Operating	Operating lease liabilities, non-current		21,~~102~~920		2,403
Total lease liabilities		$	2,~~919~~801	$	3,244

Components of lease cost were as follows:

	Three months ended January 31,				Six months ended January 31,
	Three months ended April 30,				Nine months ended April 30,
	2025		2024		2025		2024
Operating lease cost – net (a)	$	9295	$	141	$	~~187~~282	$	~~281~~472

(a) Net of $126 and $~~252~~378 of sublease income for the three and ~~six~~nine months ended ~~January~~April 3130, 2025 and 2024, respectively.

14The maturities of the Company’s lease liabilities as of April 30, 2025 are as follows:

The maturities of the Company’s lease liabilities as of January 31, 2025 are as follows:

Maturity of lease liabilities, years ending July 31,	Operating leases
2025	$	247
2026		989
2027		907
2028		833
2029		43
Total lease payments		3,019
Less: Interest (a)		(218	)
Present value of lease liabilities	$	2,801

Maturity of lease liabilities, years ending July 31,	Operating leases
2025	$	494
2026		906
2027		907
2028		833
2029		44
Total lease payments		3,184
Less: Interest (a)		(265	)
Present value of lease liabilities	$	2,919

(a)

Primarily calculated using the Company’s incremental borrowing rate.

Lease term and discount rate for the ~~six~~nine months ended ~~January~~April 3130 were as follows:

Lease term and discount rate	2025			2024
Weighted-average remaining lease term (years):
Operating leases		3.42 years			4.31 years
Weighted-average discount rate:
Operating leases		5.34	%		5.1	%

See Note 5 for cash flow information on cash paid for amounts included in the measurement of lease liabilities for the ~~six~~nine months ended ~~January~~April 3130, 2025 and 2024.

Note 10 – Accrued liabilities and current liabilities

Accrued liabilities as of the date indicated consist of:

	January 31, 2025		July 31, 2024
	April 30, 2025		July 31, 2024
Payroll, benefits and commissions	$	2,~~560~~306	$	3,459
Professional fees		~~578~~463		405
Legal		1,~~462~~600		1,235
Other		~~792~~801		615
	$	5,~~392~~170	$	5,714

Self-Insured Medical Plan

The Company self-funds medical insurance coverage for certain of its U.S. based employees. The risk to the Company is believed to be limited through the use of individual and aggregate stop loss insurance. As of ~~January~~April 3130, 2025 and July 31, 2024, the Company had established reserves of $85117 and $114, respectively, which are included in accrued liabilities for payroll, benefits and commissions, for claims that have been reported but not paid and for claims that have been incurred but not reported. The reserve is based upon the Company’s historical payment trends, claim history and current estimates.

Note 11 – Stockholders’ equity

Controlled Equity Offering

In May 2023, the Company entered into a sales agreement (the “Sales Agreement”) with B. Riley Securities, Inc. as sales agent (“Riley”). Under the Sales Agreement, the Company may offer and sell, from time to time, through Riley, shares of the Company’s common stock, par value $0.01 per share (“Shares”) having an aggregate offering price of up to $30 million. The Company pays Riley a commission of 3.0% of the aggregate gross proceeds received under the Sale Agreement. The Company is not obligated to make any sales of Shares under the Sales Agreement. The offering of Shares pursuant to the Sales Agreement will terminate upon the earlier of (a) the sale of all of the Shares subject to the Sales Agreement or (b) the termination of the Sales Agreement by Riley or the Company, as permitted therein. In May 2023, the Company filed with the SEC a “shelf” registration and sales agreement prospectus covering the Sales Agreement. A total of $150 million of securities, including those covered by the Sales Agreement, may be sold under the shelf registration which was declared effective in July 2023. There was no activity with respect to the controlled equity offering during the ~~six~~nine months ended ~~January~~April 3130, 2025 or 2024.

Incentive stock plans

In January 2011, the Company’s stockholders approved the adoption of the 2011 Incentive Plan (the “2011 Plan”) for the issuance of equity awards, including, among others, options, restricted stock, restricted stock units and performance stock units for up to 3,000,000 shares of common stock. In January 2018, the Company’s stockholders approved the amendment and restatement of the 2011 Plan (the “Amended and Restated 2011 Plan”) to increase the number of shares of common stock available for grant under the 2011 Plan by 2,000,000 shares of common stock bringing the total number of shares available for grant to 5,000,000 shares of common stock. On October 7, 2020, the Company’s Board of Directors approved the amendment and restatement of the Amended and Restated 2011 Plan, with an effective date of October 7, 2020 and subject to approval by the Company’s stockholders at the 2020 annual meeting of stockholders of the Company. The amendment and restatement of the Amended and Restated 2011 Plan was for purposes of, among other things, (i) increasing the shares of common stock available for grant under the Amended and Restated 2011 Plan by an additional 4,000,000 shares of common stock bringing the total number of shares available for grant to 9,000,000 shares of common stock and (ii) extending the term of the Amended and Restated 2011 Plan until October 7, 2030. At the fiscal 2020 annual stockholders’ meeting in January 2021, the Company’s stockholders approved the amendment and restatement of the Amended and Restated 2011 Plan.

The exercise price of options granted under the Amended and Restated 2011 Plan is equal to or greater than fair market value of the common stock on the date of grant. The Amended and Restated 2011 Plan will terminate at the earliest of (a) such time as no shares of common stock remain available for issuance under the plan, (b) termination of the plan by the Company’s Board of Directors, or (c) October 7, 2030. Awards outstanding upon expiration of the Amended and Restated 2011 Plan will remain in effect until they have been exercised or terminated, or have expired. As of January 31, 2025, there were approximately 4,304,000 shares of common stock available for grant under the Amended and Restated 2011 Plan.15

The exercise price of options granted under the Amended and Restated 2011 Plan is equal to or greater than fair market value of the common stock on the date of grant. The Amended and Restated 2011 Plan will terminate at the earliest of (a) such time as no shares of common stock remain available for issuance under the plan, (b) termination of the plan by the Company’s Board of Directors, or (c) October 7, 2030. Awards outstanding upon expiration of the Amended and Restated 2011 Plan will remain in effect until they have been exercised or terminated, or have expired. As of April 30, 2025, there were approximately 4,798,000 shares of common stock available for grant under the Amended and Restated 2011 Plan.

The Company estimates the fair value of each stock option award on the measurement date using a Black-Scholes option pricing model or the fair value of our stock at the date of grant. The fair value of awards is amortized to expense on a straight-line basis over the requisite service period. The Company expenses restricted stock awards based on vesting requirements, primarily time elapsed.

Listed below are the assumptions used to determine the fair value of options granted during the periods indicated:

	Six Months Ended January 31
	Nine Months Ended April 30
	2025			2024
Risk free interest rate %		3.03% – 5.35	%		—5.00	%
Expected term of option		3.5 years			—3.5 years
Expected stock price volatility		70	%		—70	%
Expected dividend yield		0	%		—0	%

The risk-free interest rate is based on the yield of Daily U.S. Treasury Yield Curve Rates with terms equal to the expected term of the options as of the grant date. The expected term of options is determined using the simplified method, as provided in an SEC Staff Accounting Bulletin, and the expected stock price volatility is based on the Company’s historical stock price volatility.

The amounts of share-based compensation expense recognized in the periods presented are as follows:

	Three months ended January 31,				Six months ended January 31,
	Three months ended April 30,				Nine months ended April 30,
	2025		2024		2025		2024
Stock options	$	~~105~~82	$	9890	$	~~206~~288	$	~~743~~833
Restricted stock units		7692		~~163~~117		~~143~~235		~~593~~710
	$	~~181~~174	$	~~261~~207	$	~~349~~523	$	1,~~336~~543

The following table sets forth the amount of expense related to share-based payment arrangements included in specific line items in the accompanying statements of operations:

	Three months ended January 31,				Six months ended January 31,
	Three months ended April 30,				Nine months ended April 30,
	2025		2024		2025		2024
Selling, general and administrative	$	~~173~~165	$	~~249~~199	$	~~333~~501	$	1,~~319~~518
Cost of revenues		89		128		1622		1725
	$	~~181~~174	$	~~261~~207	$	~~349~~523	$	1,~~336~~543

During the ~~six~~nine months ended ~~January~~April 3130, 2024, the Company recognized in selling, general and administrative expense $519 of share based compensation with respect to stock options and $367 of share based compensation with respect to restricted stock units as a result of the termination of the former CEO.

No excess tax benefits were recognized during the three and ~~six~~nine month periods ended ~~January~~April 3130, 2025 and 2024.

~~The following table summarizes stock option activity during the six month period ended January 31, 2025:~~16

	Options			Weighted Average Exercise Price		Weighted Average Remaining Contractual Term		Aggregate Intrinsic Value (000s)
Outstanding at July 31, 2024		2,136,870		$	2.31				—
Granted		10,000			1.11
Exercised		—			—
Cancelled or expired		(41,500	)	$	1.72
Outstanding at end of period		2,105,370		$	2.31		2.0 years		—
Exercisable at end of period		1,352,037		$	2.45		1.1 years		—

The following table summarizes stock option activity during the nine month period ended April 30, 2025:

As of January 31, 2025, the total future compensation cost related to non-vested options, not yet recognized in the statements of operations, was $253 and the weighted average period over which the remaining expense of these awards is expected to be recognized is approximately seven months. The intrinsic value of stock option awards is the value of the Company’s closing stock price on the last trading day of the period in excess of the exercise price multiplied by the number of options that are outstanding.

	Options			Weighted Average Exercise Price		Weighted Average Remaining Contractual Term	Aggregate Intrinsic Value (000s)
Outstanding at July 31, 2024		2,136,870		$	2.31			—
Granted		10,000			1.11			—
Exercised		—			—
Expired or forfeited		(535,566	)	$	2.30
Outstanding at end of period		1,611,304		$	2.29	2.3 years		—
Exercisable at end of period		1,016,304		$	2.48	1.7 years		—

17As of April 30, 2025, the total future compensation cost related to non-vested options, not yet recognized in the statements of operations, was $174 and the weighted average period over which the remaining expense of these awards is expected to be recognized is approximately six months. The intrinsic value of stock option awards is the value of the Company’s closing stock price on the last trading day of the period in excess of the exercise price multiplied by the number of options that are outstanding.

Restricted Stock Units

The following table summarizes RSU activity for the ~~six~~nine months ended ~~January~~April 3130, 2025:

	Number of RSUs outstanding			Weighted Average Fair Value per Unit at Date of Grant		Weighted Average Remaining Contractual Term		Aggregate Intrinsic Value (000s)		~~Aggregate Intrinsic Value (000s)~~
Outstanding at beginning of fiscal year		308,730		$	1.31	1.5 years	~~1.5 years~~	$	352	$	~~352~~
Granted		428,691			0.70				—		—
Vested		(~~158~~208,730	)		1.2629
Cancelled		—			—
Outstanding at end of period		528,691		$	0.82	0.9 years		$	254
Outstanding at end of period		578,691			0.87		1.25 years			$	355
Expected to vest at end of period		528,691		$	0.82	0.9 years		$	254
Expected to vest at end of period		578,691		$	0.87		1.25 years			$	355

During the three and ~~six~~nine months ended ~~January~~April 3130, 2025 ~~and 2024~~, the ~~Company~~ Company recognized shared based compensation expense for RSUs of $7692 and $~~143~~235, ~~and $163 and $593,~~ respectively. AsDuring ~~of January 31, 2025,~~ the ~~total~~three ~~future~~and ~~compensation~~nine ~~cost~~months ~~related~~ended toApril ~~non-vested RSUs~~30, ~~not yet recognized in the statements of operations~~ 2024, ~~was $413 and~~ the ~~weighted average~~Company ~~period~~recognized ~~over~~shared ~~which~~based ~~the~~compensation ~~remaining~~ expense offor ~~these~~RSUs ~~awards~~of is$117 ~~expected~~and to$710, ~~be recognized is approximately 15 months~~respectively.

As of April 30, 2025, the total future compensation cost related to non-vested RSUs, not yet recognized in the statements of operations, was $321 and the weighted average period over which the remaining expense of these awards is expected to be recognized is approximately 11 months.

A senior officer has not received 50,000 vested RSU shares which vested during the three months ended April 30, 2025.

Dividend

On October 29, 2024, the Board of Directors of the Company declared a cash dividend of $0.10 per share on its common stock, which was paid on December 2, 2024, to the holders of record as of the close of business on November 15, 2024. The dividend paid amounted to $5,324.

Note 12 – Segment reporting

The Company has one reportable segment, Products, which focuses on labeling and detection technologies from DNA to whole cell analysis, including a comprehensive portfolio of thousands of high-quality products, including antibodies, genomic probes, assays, biochemicals, and proteins. The Company’s proprietary products and technologies play central roles in translational research and drug development areas, including cell biology, genomics, assays, immunohistochemistry, and small molecule chemistry. The Company evaluates segment performance based on segment income (loss) before taxes. Costs excluded from segment income (loss) before taxes and reported as “Corporate & Other” consist of corporate general and administrative costs, which are not allocable to the Products segment.

Legal and related expenses incurred to defend the Company’s intellectual property, which may result in settlements recognized in another segment, and other general corporate matters are considered a component of the Corporate & Other segment. Legal and related expenses specific to the Products’ segment’s activities are allocated to that segment.

The following financial information represents the operating results of the reportable segments of the Company for the period indicated:

Three months ended ~~January~~April 3130, 2025

	Products			Corporate & Other			Consolidated
Revenues	$	76,~~334~~402			—		$	76,~~334~~402
Operating costs and expenses:
Cost of revenues		3,~~549~~755			—			3,~~549~~755
Research and development		479			—			479
Cost of revenues – inventory provision		163			—			163
Selling, general and administrative		2,798		$	1,760			4,558
Research and development		504			—			504
Legal and related expenses		2			348			350
Selling, general and administrative		3,128		$	1,776			4,904
Total operating costs and expenses		6,828			2,108			8,936
Legal and related expenses		7			458			465
Operating income (loss)		506			(2,108	)		(1,602	)
Total operating costs and expenses		7,557			2,234			9,791
Operating loss		(1,155	)		(2,234	)		(3,389	)
Other income (expense)
Interest		(1	)		~~463~~385			~~462~~384
Other		2—			~~124~~123			~~126~~123
Foreign exchange loss		(234	)		—			(234	)
Foreign exchange gain		508			—			508
Income (loss) before taxes	$	273		$	(1,521	)	$	(1,248	)
Loss before taxes	$	(648	)	$	(1,726	)	$	(2,374	)
Depreciation and amortization included above	$	~~228~~229		$	9389		$	~~321~~318
Share-based compensation included above:
Selling, general and administrative		3330			~~137~~138			~~170~~168
Cost of sales		86			—			86
Total	$	4136		$	~~137~~138		$	~~178~~174
Capital expenditures	$	70359		$	—37		$	70396

Three months ended April 30, 2024

	Products			Corporate & Other			Consolidated
Revenues	$	8,022			—		$	8,022

Operating costs and expenses:
Cost of revenues		4,289			—			4,289
Research and development		595		$	10			605
Selling, general and administrative		2,881			1,598			4,479
Legal and related expenses		—			692			692
Total operating costs and expenses		7,765			2,300			10,065

Operating income (loss)		257			(2,300	)		(2,043	)

Other income (expense)
Interest		37			689			726
Change in fair value of convertible debentures		—			(384	)		(384	)
Other		(31	)		125			94
Foreign exchange loss		(524	)		—			(524	)
Loss before taxes	$	(261	)	$	(1,870	)	$	(2,131	)

Depreciation and amortization included above	$	162		$	175		$	337

Share-based compensation included above:
Selling, general and administrative		32			167			199
Cost of sales		8			—			8
Total	$	40		$	167		$	207

Capital expenditures	$	123		$	20		$	143

Nine months ended April 30, 2025

	Products			Corporate & Other			Consolidated
Revenues	$	19,948			—		$	19,948

Operating costs and expenses:
Cost of revenues		10,985			—			10,985
Cost of revenues – inventory provision		415			—			415
Research and development		1,545			—			1,545
Selling, general and administrative		9,093		$	5,252			14,345
Legal and related expenses		15			1,258			1,273
Total operating costs and expenses		22,053			6,510			28,563

Operating loss		(2,105	)		(6,510	)		(8,615	)

Other income (expense)
Interest		(3	)		1,469			1,466
Other		1			372			373
Foreign exchange gain		83			—			83
Loss before taxes	$	(2,024	)	$	(4,669	)	$	(6,693	)

Depreciation and amortization included above	$	686		$	269		$	955

Share-based compensation included above:
Selling, general and administrative		95			406			501
Cost of sales		22			—			22
Total	$	117		$	406		$	523

Capital expenditures	$	867		$	37		$	904

~~Three~~Nine months ended ~~January~~April 3130, 2024

	Products			Corporate & Other			Consolidated
Revenues	$	824,~~553~~381			—		$	824,~~553~~381
Operating costs and expenses:
Cost of revenues		412,~~329~~969			—			412,~~329~~969
Research and development		~~578~~2,012		$	223			~~580~~2,035
Selling, general and administrative		39,~~284~~266			17,~~784~~284			516,~~068~~550
Legal and related expenses		2251			~~739~~2,476			~~761~~2,527
Total operating costs and expenses		824,~~213~~298			29,~~525~~783			1034,~~738~~081
Operating income (loss)		~~340~~83			(29,~~525~~783	)		(29,~~185~~700	)
Other income (expense)
Interest		34104			~~859~~2,491			~~893~~2,595
Change in fair value of convertible debentures		—			(~~383~~1,095	)		(~~383~~1,095	)
Other		2(28	)		~~117~~401			~~119~~373
Foreign exchange gain		693			—			693
Foreign exchange loss		(842	)		—			(842	)
Income (loss) before taxes	$	1,069		$	(1,932	)	$	(863	)
Loss before taxes	$	(683	)	$	(7,986	)	$	(8,669	)
Depreciation and amortization included above	$	~~172~~500		$	95374		$	~~267~~874
Share-based compensation included above:
Selling, general and administrative		4297			~~207~~1,421			~~249~~1,518
Cost of sales		1225			—			1225
Total	$	54122		$	~~207~~1,421		$	~~261~~1,543
Capital expenditures	$	—369		$	2753		$	27422

Six months ended January 31, 2025

	Products			Corporate & Other			Consolidated
Revenues	$	13,546			—		$	13,546
Operating costs and expenses:
Cost of revenues		7,230			—			7,230
Cost of revenues – inventory provision		252			—			252
Research and development		1,041			—			1,041
Selling, general and administrative		5,965		$	3,476			9,441
Legal and related expenses		8			800			808
Total operating costs and expenses		14,496			4,276			18,772
Operating loss		(950	)		(4,276	)		(5,226	)
Other income (expense)
Interest		(2	)		1,084			1,082
Other		1			249			250
Foreign exchange loss		(425	)		—			(425	)
Loss before taxes	$	(1,376	)	$	(2,943	)	$	(4,319	)
Depreciation and amortization included above	$	457		$	180		$	637
Share-based compensation included above:
Selling, general and administrative		65			268			333
Cost of sales		16			—			16
Total	$	81		$	268		$	349
Capital expenditures	$	518		$	—		$	518

Six months ended January 31, 2024

	Products			Corporate & Other			Consolidated
Revenues	$	16,359			—		$	16,359
Operating costs and expenses:
Cost of revenues		8,680			—			8,680
Research and development		1,416		$	13			1,429
Selling, general and administrative		6,383			5,687			12,070
Legal and related expenses		51			1,784			1,835
Total operating costs and expenses		16,530			7,484			24,014
Operating loss		(171	)		(7,484	)		(7,655	)
Other income (expense)
Interest		68			1,802			1,870
Change in fair value of convertible debentures		—			(711	)		(711	)
Other		3			273			276
Foreign exchange loss		(318	)		—			(318	)
Loss before taxes	$	(418	)	$	(6,120	)	$	(6,538	)
Depreciation and amortization included above	$	338		$	199		$	537
Share-based compensation included above:
Selling, general and administrative		65			1,254			1,319
Cost of sales		17			—			17
Total	$	82		$	1,254		$	1,336
Capital expenditures	$	246		$	33		$	279

Note 13 – Contingencies

Settled or Inactive Legal Matters

Ransomware Attack

In April 2023, the Company experienced a ransomware attack (the “ransomware attack”) that impacted certain critical information technology systems, principally of the discontinued operations. The Company later became aware that certain data, including names, test information, and Social Security numbers, was accessed, and in some instances, exfiltrated from the Company’s information technology systems as part of this incident. The investigation identified unauthorized access to or acquisition of clinical test information of approximately 2,470,000 individuals. The Social Security numbers of approximately 600,000 of these individuals may also have been involved. Additionally, the Company determined that some employees’ information may have been involved. The Company provided notice to the individuals whose information may have been involved, as well as to regulatory authorities, in accordance with applicable law.

2220

As a result of the ransomware attack, Enzo was subject to regulatory inquiry from the New York Attorney General, a joint inquiry from the Connecticut and New Jersey Attorneys General and an inquiry from the Utah Attorney General. All inquiries asked questions about the ransomware attack, as well as the corrective actions taken in response. The Company responded to all such inquiries, and there have been no further inquiries from the Utah Attorney General. The matters with the New York, Connecticut and New Jersey Attorneys General are now closed, as they were resolved by agreements with each of the three states effective August 8, 2024. A provision was recorded in the consolidated financial statements as of July 31, 2024 based on the settlement terms of the agreements. In September 2024, the Company paid the full settlements totaling $4,500.

Enzo was also subject to regulatory inquiries from the U.S. Department of Health and Human Services Office for Civil Rights (the “Office for Civil Rights”) regarding the ransomware attack. The Company has responded to all requests. It is not known at this time whether the Office for Civil Rights will seek a penalty against the Company. We are unable to evaluate the likelihood of an outcome, favorable or unfavorable, to the Company or to estimate the amount or range of any potential liability, if any, at this time.

In re Enzo Biochem Data Breach Litigation, No. 2:23-cv-04282 (EDNY)

In the Eastern District of New York (“EDNY”), twenty putative class actions were consolidated alleging various harms stemming from the April 2023 data incident (“EDNY Federal Action”). Lead counsel was appointed and filed a Consolidated Amended Complaint on November 13, 2023. The complaint sought to certify a federal class as well as several state subclasses. The Consolidated Amended Complaint brings various statutory and common law claims, including negligence, negligence per se, breach of fiduciary duty, breach of implied contract, breach of the implied covenant of good faith and fair dealing, violation of the New York’s General Business Law § 349, Invasion of Privacy, violations of the Connecticut Unfair Trade Practices Act, and violations of the New Jersey Consumer Fraud Act. The parties have reached a class-wide settlement agreement in the sum of $7,500 and filed an unopposed motion for preliminary approval with the Court. The Court granted the motion and set a final fairness hearing on June 10, 2025. $800 of the $7,500 settlement was paid in March 2025 to cover class action notice costs.

The parties reached a class-wide settlement agreement in the sum of $7,500 which the Court granted approval of at the final fairness hearing held on June 10, 2025. Approximately $800 of the $7,500 settlement was paid in March 2025 to cover class action notice costs. The remaining balance of approximately $6,700 must be remitted by July 10, 2025.

Other Settled or Inactive Matters

On February 25, 2022, Barry Weiner, the Company’s co-founder and President, notified the Company that he was terminating his employment as President of the Company for “Good Reason,” as defined in his employment agreement. The Company accepted Mr. Weiner’s termination, effective April 19, 2022, but disagreed with Mr. Weiner’s assertion regarding “Good Reason.” On October 24, 2023, the Company and Mr. Weiner reached an agreement resolving the dispute, and a provision was made in the financial consolidated statements as of July 31, 2023 based on the settlement agreement. The Company paid Mr. Weiner $3,600, less applicable withholding taxes, related to the agreement in November 2023.

On or about March 2, 2023, a Verified Complaint was filed in the Supreme Court of the State of New York, New York County captioned Elazar Rabbani (as plaintiff) v. Mary Tagliaferri, et al. (as defendants), Index No. 651120/2023. The Verified Complaint purports to assert causes of action for breach of fiduciary duty and corporate waste under N.Y.B.C.L. § 720, and seeks an accounting and certain injunctive relief. On August 4, 2023, defendants moved to dismiss all the causes of action asserted in the Verified Complaint. Plaintiff filed an amended complaint on or about October 4, 2023, adding, among other things, an additional cause of action for violation of N.Y.B.C.L. § 626. On October 23, 2023, defendants filed a reply in further support of their motion to dismiss. On November 6, 2023, plaintiff filed an opposition to defendants’ motion to dismiss. On November 17, 2023, defendants filed a reply brief in further support of their motion to dismiss the amended complaint. On or about July 17, 2024, the Court granted, in part, the defendants’ motion to dismiss the amended complaint. On or about August 16, 2024, plaintiff noticed an appeal from the order granting that dismissal. On or about September 18, 2024, plaintiff filed a Verified Second Amended Complaint. On October 11, 2024, the defendants filed a joint stipulation and letter requesting the court to extend the deadline to respond to the Second Amended complaint from October 18, 2024 to November 18, 2024. On November 15, 2024, the plaintiff discontinued the derivative case and the related appeal (without prejudice).

2321

In April 2024, the Company engaged in settlement negotiations with a government payer in our discontinued operations and reached a verbal settlement. The settlement was finalized in a formal written settlement agreement on August 14, 2024. The settlement resolved allegations that Enzo Clinical Labs, Inc. overbilled the Connecticut Medicaid program for testing services. The settlement was paid in August 2024 for $1,700 to resolve the State of Connecticut’s allegations and $175 was paid to settle whistleblowers’ legal fees.

Open and Active Legal Matters

Pending Class Action Litigation

Maria Sgambati et al., v. Enzo Biochem, Inc., et al., Index No. 619511/2023 (N.Y. Sup. Ct.)

This is a putative class action pending in state court alleging various harms stemming from the April 2023 data incident. The complaint seeks to certify a class of New York residents. The complaint brings claims of negligence; negligence per se; breach of implied covenant and good faith and fair dealing; breach of duty; breach of implied contract; and violations of New York’s Deceptive Acts and Practices § 349. The Company has filed a motion to stay this action pending the resolution of the EDNY Federal Action, and the motion was granted by the court. The Company ~~anticipates~~intends ~~that~~to ~~the~~seek ~~case~~dismissal ~~will~~of this beaction ~~dismissed~~ once the settlement in the EDNY Federal Action receives final approval from the court, likely sometime in 2025.

Louis v. Enzo Biochem, Inc. et al., Index No. 653281/2023 (N.Y. Sup. Ct.)

This is a putative class action pending in state court alleging various harms stemming from the April 2023 data incident. The complaint seeks to certify a class of New York citizens. The complaint brings claims of negligence; negligence per se; breach of duty; breach of implied contract; breach of implied covenant of good faith and fair dealing; and violations of New York’s Deceptive Acts and Practices § 349. The Company has filed a motion to stay this action pending the resolution of the EDNY Federal Action, and the motion remains pending. The Company ~~anticipates~~intends ~~that~~to ~~the~~seek ~~case~~dismissal ~~will~~of bethis ~~dismissed~~action once the settlement in the EDNY Federal Action receives final approval from the court, likely sometime in 2025.

Other Open and Active Legal Matters

On or about September 26, 2023, James G. Wolf, individually and as the trustee of the Wolf Family Charitable Foundation, Barbaranne R. Wolf, Stephen Paul Wolf, and Preston M. Wolf (collectively the “Petitioners”) initiated an appraisal action against the Company in the New York Supreme Court for Suffolk County. Petitioners seek an appraisal of the value of their shares in the Company. ~~The~~On ~~amount~~or ofabout ~~damages~~April ~~sought~~1, by2025, ~~the~~ Petitioners isfiled ~~unspecified.~~a Onmotion orseeking ~~about~~to compel ~~August~~an ~~21,~~“advance ~~2024,~~payment” ~~the~~of ~~Court~~80% ~~dismissed~~of ~~the~~what ~~Company’s~~they ~~Second~~contend ~~and~~to ~~Third~~be ~~Affirmative~~the ~~Defenses.~~fair Onvalue orof ~~about~~their ~~September 19~~shares, ~~2024,~~plus ~~the~~prejudgment ~~Court granted~~interest ~~the~~and ~~Company~~attorneys’ fees. ~~permission~~In totheir ~~move~~papers, ~~for~~Petitioners ~~leave~~announced totheir ~~reargue~~position, ~~the~~through ~~Court’s~~an ~~dismissal~~accompanying ~~decision.~~preliminary Onvaluation ~~or about October 16~~report, ~~2024,~~that the ~~Company~~alleged fair ~~moved~~value ~~for~~of ~~leave~~their toshares ~~reargue.~~as Onof orthe ~~about~~valuation ~~February~~date ~~20,~~was ~~2025,~~“greater ~~the~~than ~~Court~~$3.50 ~~issued~~per ashare.” ~~decision~~The ~~granting the~~ Company’s ~~motion~~disputes ~~for~~this ~~leave~~contention. toPursuant ~~reargue,~~to ~~and,~~a ~~upon~~briefing ~~reargument,~~schedule ~~adhered~~co-ordered toby ~~its~~the ~~original~~Court, ~~decision.~~in ~~The~~early ~~Company~~July ~~intends~~2025, tothe ~~continue~~Company toanticipates ~~vigorously~~filing ~~litigate~~papers ~~both~~opposing ~~(i)~~ Petitioners’ ~~alleged~~motion, ~~entitlement~~including the contention that they are entitled to ~~dissenting~~any ~~shareholder~~form ~~appraisal~~or ~~rights~~advance payment for their shares, and ~~(ii)~~their position concerning the ~~correct~~ valuation of ~~Petitioners’~~their shares.

On September 18, 2024, we received an unsealed complaint filed by whistleblowers in the Southern District of New York (“SDNY”) alleging, among other things, that the Company falsely billed Medicaid and Medicare for COVID-19 tests by utilizing inappropriate diagnostic codes to trigger payments for such tests. The SDNY advised the court that the government was not intervening in the case; however, the private plaintiffs are still pursuing the case on the governments’ behalf. The ~~court~~Court ~~ordered~~agreed ~~that~~to ~~the~~stay ~~matter~~discovery bein ~~stayed until January 15, 2025, so that~~ the ~~parties~~case ~~may~~pending ~~explore potential settlement of~~ the ~~matter. The~~submission ~~parties~~and ~~were~~decision ~~unable~~on ~~to reach a settlement and~~ the ~~case is proceeding to litigation. The~~ Company’s ~~anticipates~~anticipated ~~filing a~~ motion to dismiss the complaint (the entire case). The ~~and, pursuant to the Court~~Company’s ~~instructions,~~motion ~~will be submitting a letter~~ to ~~the~~dismiss ~~court regarding that motion by March 21, 2025. The initial conference with the court~~ is ~~scheduled~~due ~~for~~on ~~April~~June 823, 2025. We believe there are ~~meritorious~~ meritorious defenses to the claims set forth in the complaint and the Company will vigorously defend itself. A probable settlement amount is not estimable at this time.

2422

The Company terminated the employment of Elazar Rabbani, Ph.D., the Company’s former Chief Executive Officer, effective April 21, 2022. Dr. Rabbani was a director of the Company until the Annual Meeting on ~~January~~April 3130, 2024, when his term expired. Dr. Rabbani was a party to an employment agreement with the Company that entitled ~~him~~ him to certain termination benefits, including severance pay, acceleration of vesting of share-based compensation, and continuation of benefits. Based on the terms of his employment agreement, the Company estimated and accrued a charge of $2,600 in fiscal year 2022. The charge was partially offset by the reversal of bonus accruals. In May 2022, the Company paid Dr. Rabbani $2,123 in severance (the payment ~~constituted~~ constituted taxable income, but the Company did not withhold taxes from the payment). In July 2022, the Company paid Dr. Rabbani’s income and other withholding taxes of $1,024 related to that payment on Dr. Rabbani’s behalf. On July 8, 2022, the Company filed a demand for arbitration with the American Arbitration Association (the “AAA”) seeking, among other things, a declaration that the Company had fully satisfied its contractual obligations to Dr. Rabbani and seeking the tax withholding reimbursement referenced above. On August 4, 2022, Dr. Rabbani filed counterclaims in the arbitration seeking, among other things, a bonus for fiscal year 2021 and additional severance that he asserted was owed to him. AtAfter a lengthy stay of the ~~parties’~~arbitration ~~joint~~proceeding ~~request~~to allow for settlement negotiations, the parties have decided to move forward via the arbitration process. The arbitrator has ~~been~~set ~~stayed~~a ~~while~~ schedule for the ~~parties~~remainder ~~work~~of ~~towards~~the ~~resolving~~arbitration up through the ~~matter~~hearing on November 17-21, 2025. A provision was made in the consolidated financial statements as of July 31, 2023 and ~~updated~~ updated as applicable through the period ended ~~January~~April 3130, 2025 based on a reasonable estimate of loss; however, the actual exposure may differ.

The Company (as plaintiff) has brought cases in the United States District Court for the District of Delaware (“the Court”), alleging patent infringement against various companies. At this time, all of such cases have been resolved, except for one. There is currently one case that was originally brought by the Company that is still pending in the Court. In that case, Enzo alleges patent infringement of the ‘197 patent against Becton Dickinson defendants. The claims in that case are stayed.

On September 2, 2021, the U.S. Patent and Trademark Office (“PTO”) issued a non-final office action in an ex parte reexamination concerning the ‘197 Patent. In the office action, the PTO rejected certain claims of the ‘197 Patent for nonstatutory double-patenting. Enzo responded to the office action on January 3, 2022. Becton Dickinson requested another ex parte reexamination concerning the ‘197 patent on July 26, 2022. On September 16, 2022, the PTO ordered that ex parte reexamination as to certain claims of the ‘197 patent. Enzo filed a petition to terminate that second reexamination proceeding on November 16, 2022, which was denied on July 26, 2024. The PTO merged the ex parte reexamination proceedings as of August 2, 2024. On September 17, 2024, the PTO issued an office action, rejecting the claims subject to the merged reexamination proceedings. Enzo filed a response to that office action on December 17, 2024. On February 6, 2025, the PTO issued a final rejection of the claims (2, 5, 18, 20, and 228) in the ex parte reexamination proceedings. The Company is considering appeal options.

2523

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

The following discussion of our financial condition and results of operations should be read in conjunction with our consolidated financial statements and related notes and other information included elsewhere in this Quarterly Report on Form 10-Q.

Forward-Looking Statements

Our disclosure and analysis in this report, including but not limited to the information discussed in this Item 2, contain forward-looking information (within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities and Exchange Act of 1934, as amended (the “Exchange Act”)). All statements other than statements of historical fact included in this Quarterly Report on Form 10-Q, including statements regarding the Company’s future financial condition, results of operations and products in research and development may include forward-looking statements. Forward-looking statements give our current expectations or forecasts of future events. You can identify these statements by the fact that they do not relate strictly to historic or current facts. They typically use words such as “anticipate”, “estimate”, “expect”, “project”, “intend”, “plan”, “believe”, “will”, and other words and terms of similar meaning in connection with any discussion of future operations or financial performance. All forward-looking statements are subject to important factors, risks, uncertainties, and assumptions, including industry and economic conditions, that could cause actual results to differ materially from those described in the forward-looking statements.

Forward-looking statements may include, without limitation, statements relating to future actions, prospective products or product approvals, future performance or results of current and anticipated products, sales efforts, expenses, interest rates, foreign currency rates, intellectual property matters, the outcome of contingencies, such as legal proceedings, and future financial results. We cannot guarantee that any forward-looking statement will be realized, although we believe we have been prudent in our plans and assumptions. Achievement of future results is subject to risks, uncertainties and inaccurate assumptions. Should known or unknown risks or uncertainties materialize, or should underlying assumptions prove inaccurate, actual results could vary materially from past results and those anticipated, estimated or projected. As a result, investors are cautioned not to place undue reliance on any of our forward-looking statements. Investors should bear this in mind as they consider forward-looking statements. We do not assume any obligation to update or revise any forward-looking statement that we make, even if new information becomes available or other events occur in the future. We are also affected by other factors that may be identified from time to time in our filings with the Securities and Exchange Commission, some of which are set forth in Item 1A - Risk Factors in our Form 10-K filing for the fiscal year ended July 31, 2024. You are advised to consult any further disclosures we make on related subjects in our periodic reports on Forms 10-Q, 8-K and 10-K filed with the Securities and Exchange Commission. Although we have attempted to provide a list of important factors which may affect our business, investors are cautioned that other factors may prove to be important in the future and could affect our operating results.

You should understand that it is not possible to predict or identify all such factors or to assess the impact of each factor or combination of factors on our business. Consequently, you should not consider any such list to be a complete set of all potential risks or uncertainties.

Overview

The Company has operated as a life sciences company for over 45 years. The primary business of Enzo today is conducted through its Enzo Life Sciences division, which focuses on labeling and detection technologies from DNA to whole cell analysis, including a comprehensive portfolio of thousands of high-quality products, including antibodies, genomic probes, assays, biochemicals, and proteins. The Company’s proprietary products and technologies play central roles in translational research and drug development areas, including cell biology, genomics, assays, immunohistochemistry, and small molecule chemistry. The Company monetizes its technology primarily via sales through our global distribution network and licensing. Enzo Life Sciences is operated through the Company’s wholly-owned subsidiary Enzo Life Sciences, Inc. and its wholly-owned domestic and foreign subsidiaries. Costs excluded from Enzo Life Sciences financial results consist of corporate general and administrative costs and minimal therapeutic research and development expenses. These costs are reported within the consolidated financial statements as “Corporate and Other” (see Note 12 in the Notes to Consolidated Financial Statements for further segment information).

We continue to explore all strategic alternatives to maximize value for the Company’s stockholders, including without limitation, improving the market position and profitability of our services in the marketplace, and enhancing our valuation. We may pursue our goals through organic growth and strategic initiatives. Additionally, we will continue to review information regarding potential acquisitions or joint ventures, and provide information to third parties regarding potential dispositions of assets or business lines, including a potential sale of the Company, from time to time.24

26On April 22, 2025 the Company announced that its Board of Directors (the “Board”) had commenced a review of strategic alternatives after receiving multiple inquiries regarding a potential transaction with the Company. In connection with this process, the Board has formed a special committee of independent directors (the “Strategic Committee”) authorized to evaluate a broad range of opportunities to maximize value for shareholders, including a potential strategic transaction, business combination, full sale of the Company or return of excess capital to shareholders. The Strategic Committee has engaged BroadOak Capital Partners as financial advisor and to assist in evaluating any inbound expressions of interest and other potential transactions. There can be no assurance that the Company’s strategic review process will result in any transaction or other strategic outcome. The Company does not intend to disclose further developments on this strategic review process unless and until a transaction is approved and entered into, or the process is discontinued.

Discontinued operations – sale of Clinical Services business to Labcorp

Prior to July 24, 2023, we operated a clinical laboratory, doing business as Enzo Clinical Labs, which provided reference, molecular and esoteric diagnostic medical testing services in the New York, New Jersey, and Connecticut medical communities. Effective July 24, 2023, we completed the sale of certain assets used in the operation of Enzo Clinical Labs and the assignment of certain clinical lab liabilities to Laboratory Corporation of America (“Labcorp”) for an aggregate purchase price of $113.25 million in cash. In accordance with the sale, we ceased our clinical services operations. Excluded from the sale of the clinical services assets were its cash and accounts receivable. As a consequence of the sale, we have classified as discontinued operations all income and expenses attributable to the clinical services business for all periods presented.

Ransomware attack

In April 2023, the Company experienced a ransomware attack that impacted certain critical information technology systems, principally of the discontinued operation. In response, we promptly deployed containment measures, including disconnecting our systems from the internet, launching an investigation with assistance from third-party cybersecurity experts, and notifying law enforcement. We adhered to our disaster recovery plan, which enabled us to maintain operations throughout the incident response process. The Company’s facilities remained open, and we continued to provide services to patients and partners. We later became aware that certain data, including names, test information, and Social Security numbers, was accessed, and in some instances, exfiltrated from the Company’s information technology systems as part of this incident. The investigation identified unauthorized access to or acquisition of clinical test information of approximately 2.5 million individuals. The Social Security numbers of approximately 600,000 of these individuals may also have been involved. Additionally, the Company determined that some employees’ information may have been involved. The Company provided notice to the individuals whose information may have been involved, as well as to regulatory authorities, in accordance with applicable law. The Company has incurred, and may continue to incur, related expenses. The Company’s cybersecurity insurance carrier covered up to $3 million of the remediation costs related to the incident and paid service providers from the policy proceeds.

The Company remains subject to risks and uncertainties as a result of the incident, including as a result of the data that was accessed or exfiltrated from the Company’s network as noted above. Additionally, security and privacy incidents have led to, and may continue to lead to, additional regulatory scrutiny and class action litigation exposure. See Note 13 of the consolidated financial statements for discussion of litigation in connection with this incident.

NYSE Listing Notice and Transfer of Listing

On January 8, 2025, the Company received a letter from the New York Stock Exchange (the “NYSE”) notifying the Company that it iswas not in compliance with (i) Section 802.01B of the NYSE Listed Company Manual because, as of January 7, 2025, the Company’s 30 trading-day average market capitalization was less than $50 million and its last reported stockholder’s equity as of October 31, 2024 was less than $50 million and (ii) Section 802.01C of the NYSE Listed Company Manual because the average closing price of the Company’s Common Stock (the “Common Stock”) was less than $1.00 over a consecutive 30 trading-day period. The Company has a period of 18 months to cure the market capitalization and stockholder’s equity deficiencies and a period of six months to cure the average closing stock price deficiency, subject to the NYSE’s acceptance of a plan by the Company to regain compliance. The notice did not result in the immediate delisting of the Common Stock from the NYSE, but the Company ~~may~~could behave been delisted from the NYSE if it ~~does~~did not regain compliance with the foregoing continued listing standards in accordance with NYSE requirements.

~~With~~On ~~regard~~March to28, ~~the~~2025, ~~average~~we ~~closing~~notified ~~stock price deficiency,~~ the ~~Company~~NYSE ~~can~~of our ~~regain~~decision ~~compliance~~to atvoluntarily ~~any~~delist ~~time~~our ~~within~~common ~~the~~stock ~~six-month~~from ~~period~~NYSE. ~~following~~In ~~receipt~~connection ofwith the ~~NYSE's non-compliance notice if~~delisting, on the last ~~trading~~ day of ~~any~~trading ~~calendar~~of ~~month during~~ the ~~cure period, the~~ Company ~~has (i) a closing share price of at least $1.00~~’s ~~and~~common ~~(ii)~~stock ~~an average closing share price of at least $1.00 over the 30 trading-day period ending~~ on ~~the~~NYSE ~~last~~was ~~trading~~April ~~day~~17, ~~of that month~~2025. ~~Under~~ ~~the~~The ~~NYSE~~Company’s ~~listing~~common ~~rules,~~stock ~~the~~began ~~price~~trading ~~condition~~on ~~will~~OTCQX beon ~~deemed~~April ~~cured~~21, if2025 ~~the~~under ~~price promptly exceeds $1.00 per share and~~ the ~~price remains~~symbol ~~above that level for at least the following 30 consecutive trading days~~“ENZB.”

The Company submitted a plan on February 21, 2025 to cure the market capitalization, stockholder’s equity and average closing stock price deficiencies and to return to compliance with the NYSE's continued listing standards. The plan considers all available alternatives to cure the deficiencies identified by the NYSE, which plan is being reviewed by the NYSE. The Common Stock continues to be listed and trade on the NYSE, subject to the Company’s ongoing compliance with the NYSE's other continued listing standards and by the acceptance of the NYSE of this plan.25

Results of Operations from Continuing Operations

Three months ended ~~January~~April 3130, 2025 compared to ~~January~~April 3130, 2024 (in $000s)

Comparative Financial Data from Continuing Operations for the three months ended ~~January~~April 3130,

	2025			2024			Favorable (Unfavorable)			% Change
Revenues	$	76,~~334~~402		$	8,~~553~~022		$	(1,~~219~~620	)		(1420	)
Operating costs and expenses:
Cost of revenues		3,~~549~~755			4,~~329~~289			~~780~~534			1812
Research and development		479			580			101			17
Cost of revenues – inventory provision		163			—			(163	)		**
Selling, general and administrative		4,558			5,068			510			10
Research and development		504			605			101			17
Legal and related expenses		350			761			411			54
Selling, general and administrative		4,904			4,479			(425	)		(10	)
Total operating costs and expenses		8,936			10,738			1,802			17
Legal and related expenses		465			692			227			33
Operating loss		(1,602	)		(2,185	)		583			27
Total operating costs and expenses		9,791			10,065			274			3
Operating loss		(3,389	)		(2,043	)		(1,346	)		(66	)
Other income (expense):
Interest, net		~~462~~384			~~893~~726			(~~431~~342	)		(4847	)
Fair value adjustment		—			(~~383~~384	)		~~383~~384			100
Other		~~126~~123			~~119~~94			729			631
Foreign exchange (loss) gain		(234	)		693			(927	)		**
Foreign exchange gain (loss)		508			(524	)		1,032			**
Loss before income taxes	$	(12,~~248~~374	)	$	(~~863~~2,131	)	$	(~~385~~243	)		(4511	)

not meaningful

Consolidated Results:

The “2025 period” and the “2024 period” refer to the three months ended ~~January~~April 3130, 2025 and 2024, respectively.

Revenues were $76.34 million in the 2025 period and $8.50 million in the ~~2024~~ 2024 period, a decrease of approximately $1.26 million or 1420% due to a decline in all geographic areas of our customer base ~~due~~related to ~~declining~~general ~~market~~continued ~~demand,~~headwinds ~~primarily~~ in ~~our~~the ~~markets~~life ~~outside~~sciences oftools ~~the U.S.~~space, ~~related~~including todecreases ~~general continued headwinds~~ in ~~the~~government ~~life~~grants, ~~sciences~~reduced ~~tools~~R&D ~~space~~budgets, ~~and~~tariffs uncertainty and the timing of large orders fulfillment.

The cost of revenues was $3.58 million in the 2025 period and $4.3 million in the 2024 period, a decrease of $0.85 million or 1812% due to lower revenues and the impact of cost containment initiatives. The gross profit margin was approximately 5239% (41% excluding the inventory provision of $163) and 4947% in the 2025 and 2024 periods, respectively. The decline in the 2025 period gross profit was ~~positively~~driven ~~impacted~~ by athe ~~more~~reduction ~~profitable~~in ~~mix~~revenues, ofwhich ~~products~~did ~~sold~~ not fully cover overhead burden and ~~cost~~other fixed ~~containment~~manufacturing ~~measures~~costs.

~~Research~~The ~~and~~cost ~~development~~of ~~expenses~~revenues ~~were~~– ~~$0.5~~inventory ~~million~~provision inwas ~~the 2025 period~~approximately ~~and~~ $0.62 million infor ~~the~~inventory ~~2024~~we ~~period,~~intended ato ~~decrease~~use ofin ~~$0.1~~manufacturing ~~million~~and orsell ~~17%.~~to ~~There~~laboratory ~~was~~customers anwhich ~~emphasis~~we onfully ~~manufacturing~~reserved ~~effort~~ in the 2025 period. ~~During~~This ~~the~~provision ~~2024~~represents ~~period~~approximately ~~there~~2.5% ~~was~~of athe ~~greater~~2025 ~~investment~~period’s ~~in research and development resources and materials consumed~~revenues.

Selling, general and administrative expenses were $4.6 million during the 2025 period versus $5.1 million during the 2024 period, a decrease of $0.5 million or 10%. The decrease was in the Products segment as compared to 2024 period due to lower headcount, sales commissions, and travel expenses.26

~~Legal~~Research and ~~related~~development expenses were $0.45 million ~~during~~in the 2025 period and $0.86 million in the 2024 period, a decrease of $0.41 million or 5417%. ~~During~~due ~~the~~to ~~2024~~cost ~~period,~~containment wemeasures ~~required significantly more legal expertise~~ and ~~assistance~~lower ~~associated~~patent ~~with corporate matters~~expense.

~~Interest income~~Selling, ~~net~~general ~~was~~and administrative expenses were $04.59 million in during the 2025 period ~~compared~~versus to $04.95 million induring the 2024 period, aan ~~decrease~~increase of $0.4 million or 4810%. ~~due~~For to the ~~decrease~~Products segment there was an increase in ~~the~~administrative ~~balance~~and ofinformation ~~cash~~technology ~~held~~costs. inFor athe ~~money~~Other ~~market~~segment, ~~account and~~there awere ~~decline~~higher instrategic ~~the~~consulting ~~interest~~costs, ~~rate~~health and ~~earned~~life ~~due~~insurance, toand ~~Federal~~bonus ~~Reserve~~accruals, ~~actions~~as tothe ~~lower~~2024 ~~discount~~period ~~rates~~had bonus reversals.

WeLegal ~~recorded~~and arelated ~~fair~~expenses ~~value~~were ~~adjustment~~$0.5 ~~charge~~million ofduring ~~approximately~~the 2025 period and $0.47 million ~~for~~ ~~the Debentures~~ in the 2024 period, ~~based~~a ondecrease ~~their~~of ~~fair~~$0.2 ~~value~~million asor of33%. ~~January~~During ~~31,~~the 2024 period, ~~which~~we ~~were~~required ~~due~~more ~~and~~legal ~~fully~~expertise ~~repaid~~and inassistance associated ~~May~~with ~~2024~~corporate matters.

Interest income, net was $0.4 million in the 2025 period compared to $0.7 million in the 2024 period, a decrease of $0.3 million or 47% due to the decrease in the balance of cash held in a money market account and a decline in the interest rate earned due to Federal Reserve actions to lower discount rates.

In the 2024 period we recorded a fair value adjustment charge of approximately $0.4 million for the convertible debentures based on their fair value as of April 30, 2024, and which were due and fully repaid in May 2024.

Other income in both periods is primarily from the subletting of a portion of our office space in New York, NY.

The foreign exchange ~~loss~~gain recognized by the Products segment during the 2025 period was $0.25 million compared to a ~~gain~~loss of $0.75 million in the 2024 period, ana ~~unfavorable~~favorable variance of $01.90 million. ~~The~~At ~~foreign~~the end ~~exchange~~of ~~loss in~~ the 2025 period ~~was~~as ~~due~~compared to its start, the ~~revaluation~~British ofpound ~~intercompany~~and ~~balances~~Swiss ~~denominated~~franc ingreatly ~~European~~appreciated ~~currencies~~compared ~~into~~to ~~Swiss~~the ~~francs,~~U.S. dollar as a result ~~which~~of ~~appreciated~~U.S. ~~slightly~~economic policies, bywhich ~~our~~resulted ~~Swiss~~in ~~subsidiary.~~revaluation ~~The~~gains ~~2024~~on ~~period~~certain ~~revaluation~~assets ~~gain~~and ~~was~~liabilities ~~due~~carried toin ~~appreciation~~those foreign currencies. At the end of the ~~Swiss~~2024 ~~franc~~period as compared to its start, ~~Euro and~~those ~~British~~foreign ~~pound~~currencies asdepreciated in value compared to the U.S. dollar, ~~when~~resulting in ~~intercompany~~revaluation ~~balances~~losses ~~were~~on ~~higher, especially~~ those ~~denominated~~certain inassets ~~the~~and Uliabilities.~~S. dollar.~~

2827

Results of Operations from Continuing Operations

~~Six~~Nine months ended ~~January~~April 3130, 2025 compared to ~~January~~April 3130, 2024 (in $000s)

Comparative Financial Data from Continuing Operations for the ~~six~~nine months ended ~~January~~April 3130,

	2025			2024			Favorable (Unfavorable)			% Change
Revenues	$	1319,~~546~~948		$	1624,~~359~~381		$	(24,~~813~~433	)		(1718	)
Operating costs and expenses:
Cost of revenues		710,~~230~~985			812,~~680~~969			1,~~450~~984			1715
Cost of revenues – inventory provision		~~252~~415			—			(~~252~~415	)		**
Research and development		1,~~041~~545			12,~~429~~035			~~388~~490			2724
Selling, general and administrative		914,~~441~~345			1216,~~070~~550			2,~~629~~205			2213
Legal and related expenses		~~808~~1,273			12,~~835~~527			1,~~027~~254			5650
Total operating costs and expenses		1828,~~772~~563			2434,~~014~~081			5,~~242~~518			2216
Operating loss		(58,~~226~~615	)		(79,~~655~~700	)		21,~~429~~085			3211
Other income (expense):
Interest, net		1,~~082~~466			12,~~870~~595			(~~788~~1,129	)		(4244	)
Fair value adjustment		—			(~~711~~1,095	)		~~711~~1,095			100
Other		~~250~~373			~~276~~373			~~(26~~—	)		(9—	)
Foreign exchange loss		(425	)		(318	)		(107	)		(34	)
Foreign exchange gain (loss)		83			(842	)		925			110
Loss before income taxes	$	(46,~~319~~693	)	$	(68,~~538~~669	)	$	21,~~219~~976			3423

not meaningful

Consolidated Results:

The “2025 period” and the “2024 period” ~~refer~~ refer to the ~~six~~nine months ended ~~January~~April 3130, 2025 and 2024, respectively.

Revenues were $1319.59 million in the 2025 period and $1624.4 million in ~~the~~ the 2024 period, a decrease of approximately $24.84 million or 1718% due to a decline in all geographic areas of our customer base ~~due~~related to ~~declining~~general ~~market~~continued ~~demand,~~headwinds ~~primarily~~ in ~~our~~the ~~markets~~life ~~outside~~sciences oftools ~~the U.S.~~space, ~~related~~including todecreases ~~general~~in ~~continued~~government ~~headwinds~~grants, inreduced ~~the~~R&D ~~life~~budgets, ~~sciences tools~~tariffs ~~space~~uncertainty and the timing of large orders fulfillment.

The cost of revenues was $711.20 million in the 2025 period and $813.~~7 million~~0 million in the 2024 period, a decrease of $12.50 million or 1715% due to lower revenues and the impact of cost containment initiatives. The gross profit margin was approximately 4743% in(45% ~~both~~excluding the inventory provision) in the 2025 period and 47% 2024 ~~periods~~period and was driven by the reduction in revenues, which did not fully cover overhead burden and other fixed manufacturing costs.

The cost of revenues – inventory provision was approximately $0.34 million for ~~raw material~~ inventory we intended to use in manufacturing and sell to laboratory customers which we fully reserved in the 2025 period. This provision represents approximately 2% of the 2025 period’s revenues.

Research and development expenses were $1.05 million in the 2025 period and $12.40 million in the 2024 period, a decrease of $0.45 million or 2724%. There was an emphasis on manufacturing effort in the 2025 period. ~~During~~and ~~the~~cost ~~2024~~containment ~~period~~measures, ~~there~~including ~~was~~reduction ~~a greater investment~~ in ~~research~~patent ~~and development resources and materials consumed~~expense.

Selling, general and administrative expenses were $914.43 million during the 2025 period versus $1216.06 million during the 2024 period, a decrease of $2.62 million or 2213%. The Other segment expense declined $2.20 million primarily due to severance provisions and accelerated recognition of share based compensation in the 2024 period related to a former senior officer. The Products segment expense decreased $0.42 million as compared to 2024 period due to lower headcount, sales commissions, travel expenses, and bonus accruals.

2928

Legal and related expenses were $01.83 million during the 2025 period and $12.85 million in the 2024 period, a decrease of $1.03 million or 5650%. During the 2024 period, we required significantly more legal expertise and assistance associated with corporate matters as discussed in Note 13 Contingencies.

Interest income, net was $1.15 million in the 2025 period compared to $12.96 million in the 2024 period, a decrease of $01.81 million or 4244% due to a decrease in the balance of cash held in a money market account and a decline in the interest rate earned due to Federal Reserve actions to lower discount rates.

WeIn the 2024 period we recorded a fair value adjustment charge of approximately $01.71 million for the ~~Debentures~~convertible indebentures ~~the 2024 period~~ based on their fair value as of ~~January~~April 3130, 2024, which were due and fully repaid in May 2024.

Other income in both periods is primarily from the subletting of a portion of our office space in New York, NY.

The foreign exchange ~~loss~~gain recognized by the Products segment during the 2025 period was $0.41 million compared to a loss of $0.38 million in the 2024 period, ana ~~unfavorable~~favorable variance of $0.19 million. ~~The~~At ~~foreign~~the ~~exchange~~end ~~revaluation~~of ~~loss~~the in2025 ~~both~~period ~~periods~~as ~~was~~compared ~~due~~ to ~~the~~its ~~depreciation~~start, of the ~~Swiss~~British ~~franc,~~pound ~~Euro~~ and ~~British~~Swiss ~~pound~~franc asslightly appreciated compared to the U.S. dollar., which ~~Those~~resulted ~~currencies~~in ~~depreciated~~small ~~more~~revaluation gains on certain assets and liabilities carried in those foreign currencies. At the ~~2025~~end of the 2024 period as ~~than~~compared to its start, those foreign currencies has significantly depreciated in value compared to the ~~2024~~U.S. ~~period~~dollar, resulting in larger revaluation losses on those certain assets and liabilities.

Liquidity and Capital Resources

Our aggregate cash and cash equivalents as of ~~January~~April 3130, 2025 was $4036.3 7 million and $52.34 million as of July 31, 2024. The decrease of $1215.07 million in our cash and cash equivalents balance as of ~~January 31,~~April 30, 2025 was primarily due to the period net loss, cash used to pay down accrued liabilities, particularly those of the discontinued operations, and the payment of a dividend of $5.3 million, partially offset by the release from escrow of $5.0 million, as discussed below. Based on the current available working capital, management believes the Company has sufficient funds to meet its operating requirements for at least the next twelve months from the date of the filing of this report. Our working capital was $3531.03 million and $45.2 million as of ~~January~~April 3130, 2025 and July 31, 2024, respectively.

Net cash used in operating activities during the 2025 period was $1114.02 million, compared to $2225.32 million during the 2024 period, a favorable variance of $11.30 million, primarily due to the smaller net loss from continuing operations in the 2025 period and the larger paydowns of accounts payable – trade and accrued liabilities in the 2024 period.

Net cash provided by investing activities during the 2025 period was approximately $4.51 million and represents the release of cash held in escrow from the Labcorp Asset Purchase Agreement which closed in July 2023, partially offset by capital expenditures of $0.9 million. Net cash used in investing activities during the 2024 period was approximately $0.3 4 million for capital expenditures.

Net cash used in financing activities in the 2025 period was $5.56 million and primarily represents the payment of a $5.3 million dividend in December 2024. Cash used in the 2024 period amounted to $0.56 million primarily for taxes paid on bonuses paid in stock.

Labcorp Asset Purchase Agreement and release of Cash in Escrow

We had indemnification obligations to Labcorp under the Asset Purchase Agreement that could have required us to make payments to Labcorp and other related persons for any damages incurred by Labcorp or such related persons as a result of any breaches of our representations, warranties, covenants or agreements contained in the Asset Purchase Agreement, or arising from retained liabilities or certain third-party claims specified in the Asset Purchase Agreement. Generally, our representations and warranties survived for a period of 15 months from the closing date, which was July 24, 2023, other than certain fundamental representations, which survive until the expiration of the applicable statute of limitations. There is an indemnification cap with respect to a majority of the Company’s indemnification obligations under the Asset Purchase Agreement with the exception of claims for actual fraud, the breach of any fundamental representations and certain other items, which are subject to a higher indemnification cap (up to the purchase price).

3029

Pursuant to the terms of the Asset Purchase Agreement, we, Labcorp, and an escrow agent entered into an Escrow Agreement at closing, pursuant to which Labcorp deposited $5 million of the aggregate purchase price of the clinical service business into an escrow account in order to satisfy, in whole or in part, certain of our indemnity obligations, if any, that arose under the Asset Purchase Agreement. Labcorp made no claims and required only a reimbursement of certain legal fees it had incurred, which were immaterial. On October 30, 2024, the escrowed funds of $5.0 million were released to the Company.

Off Balance Sheet Arrangements

The Company does not have any “off-balance sheet arrangements” as such term is described in Item 303 of Regulation S-K.

Critical Accounting Policies and Estimates

General and estimates

The Company’s discussion and analysis of its financial condition and results of operations are based upon Enzo Biochem, Inc.’s consolidated financial statements, which have been prepared in accordance with U.S. GAAP. The preparation of these financial statements requires the Company to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses. These estimates and judgments also affect related disclosure of contingent assets and liabilities.

On an on-going basis, we evaluate our estimates, including those related to contractual expense, allowance for expected credit losses, inventory, and income taxes. The Company bases its estimates on experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.

Contingencies

Product revenues

Products revenues consist of the sale of single-use products used in the identification of genomic information and are recognized at a point in time following the transfer of control of such products to the customer, which generally occurs upon shipment. Payment terms for shipments to end-user and distributor customers may range from 30 to 90 days. Any claims for credit or return of goods may be made generally within 30 days of receipt. Revenues are reduced to reflect estimated credits and returns, although historically these adjustments have not been material. Taxes collected from customers relating to product sales and remitted to governmental authorities are excluded from revenue. Amounts billed to customers for shipping and handling are included in revenue, while the related shipping and handling costs are reflected in cost of products.

Accounts Receivable

Accounts receivable are reported at realizable value, net of expected credit losses, which is estimated and recorded in the period of the related revenue.

As of ~~January~~April 3130, 2025 and July 31, 2024, Products accounts receivable, net were $4,~~245~~309 and $3,988, respectively. As of ~~January~~April 3130, 2025 and July 31, 2024, these totals include foreign receivables, net, of ~~$881~~ $782 and $1,185, respectively.

Inventory

The Company values inventory at the lower of cost (first-in, first-out) or net realizable value. Work-in-process and finished goods inventories consist of material, labor, and manufacturing overhead. Write downs of inventories to net realizable value are based on a review of inventory quantities on hand and estimated sales forecasts based on sales history and anticipated future demand. Unanticipated changes in demand could have a significant impact on the value of our inventory and require additional write downs of inventory which would impact our results of operations.

Long-Lived Assets

The Company reviews the recoverability of the carrying value of long-lived depreciable assets of an asset or asset group for impairment if indicators of potential impairment exist. Should indicators of impairment exist, the carrying values of the depreciable assets are evaluated in relation to the operating performance and future undiscounted cash flows of an asset or asset group. The net book value of the depreciable long lived asset is adjusted to fair value if its expected future undiscounted cash flow is less than its book value.

During the ~~six~~nine months ended ~~January~~April 3130, 2025 and 2024 there was no ~~impairment~~ impairment of depreciable long-lived assets used in continuing operations.

Item 3. Quantitative and Qualitative Disclosures About Market Risk

As a smaller reporting company, we are not required to provide the information required by this Item.

Item 4. Controls and Procedures

Evaluation of Disclosure Controls and Procedures

As of the end of the period covered by this report, the Company’s management conducted an evaluation (as required under Rules 13a-15(b) and 15d-15(b) under the Exchange Act) of the Company’s “disclosure controls and procedures” (as such term is defined under the Exchange Act), under the supervision and with the participation of each of our principal executive officer and principal financial officer. Based on the evaluation of our Disclosure Controls, our principal executive officer and principal financial officer have concluded that, as of ~~January~~April 3130, 2025, our Disclosure Controls were effective to to ensure that information required to be disclosed by us in the reports we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms and is accumulated and communicated to our management, including our principal executive officer and principal financial officer, as appropriate to allow timely decisions regarding required disclosure.

Changes in Internal Control Over Financial Reporting

There were no changes in our internal control over financial reporting that occurred during the period ended ~~January~~April 3130, 2025 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

3231

PART II - OTHER INFORMATION

Item 1. Legal Proceedings

There have been no other material developments with respect to previously reported legal proceedings discussed in the annual report on Form 10-K for the fiscal year ended July 31, 2024 filed with the Securities and Exchange Commission, other than as noted in Note 13 to these Consolidated Financial Statements as of ~~January~~April 3130, 2025.

Item 1A. Risk Factors

There have been no material changes from the risk factors disclosed in Part 1, Item 1A of the Company’s Annual Report on Form 10-K for the fiscal year ended July 31, 2024.

Item 2. Unregistered Sales of Equity Securities, Use of Proceeds, and Issuer Purchases of Equity Securities

None.

Item 3. Defaults Upon Senior Securities

None.

Item 4. Mine Safety Disclosures

Not applicable.

Item 5. Other Information00

None.

Item 6. Exhibits

Exhibit No.		Exhibit

31.1		Certification of Kara Cannon pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

31.2		Certification of Patricia Eckert pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

32.1		Certification of Kara Cannon pursuant to 18 U.S.C. §1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

32.2		Certification of Patricia Eckert pursuant to 18 U.S.C. §1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

101. INS*		Inline XBRL Instance Document.

101. SCH*		Inline XBRL Taxonomy Extension Schema Document.

101. CAL*		Inline XBRL Taxonomy Extension Calculation Linkbase Document.

101.DEF*		Inline XBRL Taxonomy Extension Definition Linkbase Document.

101.LAB*		Inline XBRL Taxonomy Extension Label Linkbase Document.

101.PRE*		Inline XBRL Taxonomy Extension Presentation Linkbase Document.

104		Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).

XBRL (Extensible Business Reporting Language) information is being furnished and not filed for purposes of Sections 11 and 12 of the Securities Act of 1933 and Section 18 of the Securities Exchange Act of 1934.

3332

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

	ENZO BIOCHEM, INC.
	(Registrant)
Date: March 17, 2025	by:	/s/ Patricia Eckert
Date: June 16, 2025	by:	/s/ Patricia Eckert
		Chief Financial Officer and Principal Accounting Officer

3433

Filing Compare · ENZO BIOCHEM INC